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Abstract 
 
External beam radiation therapy is an effective and widely used focal cancer therapy. However, 
due to anatomical changes during radiation therapy, both in the tumor and in the normal tissue, 
the delivered radiation dose can deviate from the planned radiation dose. These responses may 
compromise the delivery of the most effective treatment and lead to an increased risk of 
complications in normal tissues. The ability to estimate the delivered radiation to the tumor and 
normal tissues with high accuracy requires modeling the patient response to dose. Modern 
medical imaging, such as computed tomography (CT) and medical resonance imaging (MRI), 
provides a method to evaluate spatial and functional changes of the tumor and normal tissue over 
the course of radiation therapy. A comprehensive evaluation of these changes requires 
identification of the tumor and normal tissue, through image segmentation, and accurate 
alignment of images, through image registration. In the head and neck region, varying angles of 
neck flexion, rapid tumor response and weight loss cause early changes in healthy tissue. In the 
abdominal region, motion due to breathing and digestion cause changes in the tumor position and 
normal structures. When the deviations between delivered and planned dose are great enough, 
the radiation treatment plan should be reoptimized, in order to ensure that the tumor is 
adequately treated and that the normal tissue is maximally avoided. Estimating the delivered 
dose to sufficient accuracy is therefore an important requirement for effective adaptive 
replanning. This dissertation work develops different techniques based on biomechanical models 
 xiv 
of the anatomical changes to improve estimates of delivered dose, which can ultimately lead to 
improvements in treatment adaptation strategies as well as a better understanding of toxicity. A 
series of experiments based on finite element modeling were conducted to model the 
uncertainties between planned and delivered dose, as well as the potential impact of modeling on 
different organ sites. Abdominal normal tissue complication probability models were developed 
based on estimated delivered dose and their accuracy compared to traditional models based on 
planned dose. Following this study, a predictive model was developed for the head and neck site, 
in order to find how early in treatment significant deviations in planned and delivered dose could 
be predicted. After seeing the large potential deviations between planned and delivered dose in 
the head and neck site, a comprehensive study was conducted to model the changes that 
potentially cause these large deviations. This comprehensive head and neck model was 
developed in two steps; first, the positional changes due to flexion were resolved and second, the 
dose response to the parotid glands was modeled using finite element modeling. Each clinical 
site poses different challenges, and this dissertation work highlights two areas in which modeling 
the deviations between planned and delivered dose will improve advanced adaptive radiation 
therapy.   
 1 
Chapter 1. Introduction  
The majority of cancer patients are treated with radiation therapy at some point during their 
treatment process. Radiation therapy is a comprehensive part of a treatment plan and is used to 
target cancer and spare normal tissue. The traditional approach has for decades consisted of 
planning a dose distribution from a single image of the anatomy and then delivering the 
treatment during several daily dose delivery fractions. However, the anatomy of the patient 
constantly changes throughout the duration of treatment, potentially causing variation in the dose 
to the tumor and other organs.  In order to ensure proper delivery of the prescribed dose to the 
target, image-guided radiotherapy has been developed based on the acquisition of images before 
each treatment fraction in order to reduce uncertainties in the localization of the target (tumor) 
during dose delivery. More recently, adaptive treatment strategies taking advantage of these 
images have been proposed, consisting of evaluating the delivered dose, identifying variations 
from planning, updating treatment decisions, and modifying the treatment plan accordingly. 
These novel patient-specific treatment strategies lead to more accurate radiation therapy, but 
there still exists the need to evaluate the impact of these strategies.  
 
 Cancers in the liver and head and neck  
 
Liver cancer is the sixth most common cancer worldwide, and accounts for 841,080 cases and 
5% of all cancers diagnosed globally in 2018 [1]. The most common primary liver cancer is 
hepatocellular carcinoma (HCC). The highest incidence of HCC occurs in East Asia and sub-
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Saharan Africa, where cases are mainly due to the hepatitis B virus [2]. However, HCC is the 
fastest growing cause of cancer deaths in the United States, which is linked to the hepatitis C 
virus. Additionally, non-alcoholic fatty liver disease (NAFLD) as well as obesity are also causes 
linked to the increased prevalence of HCC in the United States. HCC has a 5-year survival rate 
below 12% [2].  
 
Cancers in the head and neck (HN) region include lip and oral cavity, nasopharynx, oropharynx, 
hypopharynx, and salivary glands. These cancers account for 710,237 cases and 4% of all 
cancers diagnosed worldwide in 2018 [1]. HN cancer is also more common in eastern than in 
western countries. The highest incidence of HN cancers occur in Southeast Asia [3], where risk 
factors include the areca nut and smokeless tobacco [4]. Incidence of HN cancer is relatively low 
in the United States (3%) [5], and is primarily due to smoking and alcohol use [6]. Similar to 
liver cancer, HN cancer can also be caused by viruses; there has recently been a rise in the 
incidence of oropharyngeal cancers due to the human papillomavirus (HPV) [7]. The overall 5-
year survival rate for HN cancers is estimated between 56% and 75% [8-10]. 
 
 Treatment modalities 
 
1.2.1 Liver cancer 
 
While surgery to remove the tumor is the best option for cure of liver cancer, it isn’t always 
possible based on the location and size of the tumor [11]. Most chemotherapy drugs are not 
effective in the treatment of liver cancer, although hepatic artery infusion, which involves the 
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hepatic artery directly receiving the drugs, has been successful in early studies [12]. Small 
tumors can be treated with ablation therapy, which is performed by inserting a needle into the 
tumor to apply heat, cold, radio waves, or alcohol to kill cancer cells. This method is the most 
effective in tumors that are within 3cm in diameter [13]. For tumors between 3cm and 5cm in 
diameter, ablation therapy is most effective when used with embolization [13], which aims to 
block the blood supply to cancer cells. Embolization can also be combined with chemotherapy 
for trans-arterial chemoembolization (TACE). External beam radiation therapy (EBRT) is 
considered for liver cancer in cases where the other treatment modalities are not appropriate, 
however non-randomized studies show it may as effective as ablation [14]. Radiation therapy can 
be used for primary liver cancer as well as metastases in the liver, and can be delivered to tumors 
of various sizes. Additionally, radiation therapy has been used as a bridge to transplantation in 
cases of HCC [15].  
 
1.2.2 Head and neck cancer 
 
Similarly to liver cancer, surgery is commonly used for the treatment of HN cancer. 
Chemotherapy, in contrast to the treatment of liver cancer, is effective in the treatment of HN 
cancer. Surgeries performed for the treatment of HN cancer include laser surgery, which is used 
for early-stage tumors, excision, dissection (of the neck or lymph nodes), and reconstructive 
surgery. These surgeries can lead to side effects such as difficulty breathing due to swelling, 
hearing loss, voice alterations, facial disfigurement, and impaired speech. Additionally, patients 
can develop problems with chewing and swallowing, which can lead to the need for a feeding 
tube [16]. Chemotherapy is another method used to treat HN cancer, and involves the delivery of 
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drugs to the bloodstream to kill cancer cells. Chemotherapy can lead to gastro-intestinal (GI) 
problems, hair loss, risk of infection, and fatigue [17]. More than half of HN cancer patients are 
prescribed external beam radiation therapy (EBRT) [18] alone or in conjunction with surgery (in 
the case of advanced HN cancers). Head and neck cancer patients can also be treated 
concurrently with EBRT and chemotherapy (chemoradiation).  
 
 Historical review of dose accumulation, adaptive radiation therapy, and 
toxicity modeling in radiation therapy  
 
1.3.1 Liver cancer 
 
SBRT is a type of EBRT that delivers precise high dose radiation beams over 1-5 fractions and 
can be used to treat liver cancer and spare surrounding normal tissue. Several studies have 
demonstrated treatment efficacy using SBRT for liver cancer [19-21]. Recently, Scorsetti et al 
[19] analyzed 5-year local control, overall survival, progression free survival, and toxicity rates 
for 61 patients treated with SBRT for inoperable liver metastases. The long term results of this 
study suggested the safety and efficacy of SBRT for these patients. Dawson et al [20] studied 79 
patients with liver cancer treated with individualized SBRT. Dose-limiting toxicity for these 
patients was not observed, indicating that individualized, image-guided SBRT for liver is a 
feasible treatment method. Kwon et al [21] evaluated the long-term effects of 42 patients treated 
with SBRT for inoperable primary small HCC. The long term results of this study found 
complete response for the in-field lesion in 60% of the patients and overall 3-year survival of 
59%, indicating that SBRT is promising for inoperable small HCC.  
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Delivering high doses of radiation to tumors in the liver is challenging due to the position of liver 
in the abdomen near radiosensitive gastrointestinal organs. The stomach and duodenum develop 
toxicity (e.g. nausea, vomiting and bleeding) from radiation treatment and are commonly the 
dose-limiting organs during treatment [22]. Studies have shown that toxicity of these luminal GI 
structures are predicted by maximum dose to a small volume [22]. As these organs are situated 
so close to the liver, the dose to the tumor may need to be limited. Substantial deformation can 
occur in this region due to breathing and stomach filling [23,24]. While weight loss and tumor 
response are typically not observed over the course of treatment of liver cancer, random 
variations occur potentially causing the normal tissue to receive more dose than what was 
planned [25] increasing the risk of toxicity, which makes it an interesting area to study the 
uncertainties between planned and delivered radiation dose. 
 
1.3.2 Head and neck cancer 
 
The current most common radiation therapy delivery method for HN cancer, usually post-
surgery and often concurrently with chemotherapy, is intensity modulated radiation therapy 
(IMRT). IMRT employs non-uniform beam intensities, and the plans are typically developed 
with inverse planning and optimization algorithms. IMRT, like SBRT, can precisely target the 
tumor while sparing surrounding normal tissue, which is important for parallel organs. This 
treatment method allows the elevation of dose to the tumor volume and the reduction of dose to 
surrounding normal tissues. HN IMRT usually delivers 60-70Gy over 30-35 fractions. This 
 6 
method has been shown to improve target coverage from the traditional radiation therapy 
methods for HN cancer treatment [26,27], with reports of local control exceeding 90% [28,29].   
 
Treating HN cancer patients can be challenging due to the anatomical changes of the patient 
during radiation therapy, due to weight loss, patient positioning, and dose-response of the tumor. 
During radiation therapy to HN cancers, there is often a rapid response of normal tissues near the 
target volume [30,31]. Studies have shown a rapid change in volume for the parotid glands over 
the course of radiation treatment, and this volumetric response has been correlated with radiation 
dose [32]. These rapid changes observed during radiation therapy make the HN region an 
important area to study the uncertainties between planned and delivered radiation dose.  
 
1.3.3 Toxicity from radiation therapy 
 
As the dose increases during radiation therapy, the probability of tumor control increases, but so 
does the likelihood of complications for healthy tissue. For optimal radiation therapy, the goal is 
to minimize normal tissue complication probability (NTCP) and maximize tumor control 
probability (TCP) [33]. NTCP models aim to quantify the risk of complications based on 
radiation dose to the patient using a simplified metric [34]. An optimal dose is one that gives the 
best separation of tumor control and reasonable risk of complication for normal tissue (Fig 1-1). 
Dose constraints placed on the OAR during radiation treatment planning are defined based on 
population models such as NTCP. The use of these types of models are critical in optimizing the 
radiation dose. Hence, it is crucial that these models are as accurate as possible.  
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The most popular NTCP model has been proposed by Lyman [35] in 1985. The model follows a 
sigmoidal relationship between dose and probability as defined by equation (1-1):  
 
 
𝑁𝑇𝐶𝑃 = (2𝜋)−1/2∫ exp (−
𝑡2
2
)𝑑𝑡
[𝐷−𝑇𝐷50(𝑣)]/[𝑚𝑇𝐷50(𝑣)]
−∞
 
 
(1-1) 
 
where D is the dose, TD50 is the whole organ dose where NTCP is 50%, v is the fractional 
volume, and m is the slope of the curve.   The model for TCP also follows a sigmoidal 
relationship (Eq. 1-2): 
 
 𝑇𝐶𝑃 = 𝑒−𝑁(𝑆𝐹2)
𝐷
𝐷𝑟𝑒𝑓
𝛼
𝛽
+
𝐷
𝑛
𝛼
𝛽
+𝐷𝑟𝑒𝑓
 
 
(1-2) 
where N represents the amount of clonogenic cells that reside in the tumor, SF2 represents the 
fraction of cells that survived the reference radiation dose (Dref), D represents the dose, n 
represents the amount of treatment fractions, and α/β represents the dose at which equal numbers 
of cells are killed from the linear and quadratic components. Figure 1-1 represents an example of 
an NTCP function and the associated TCP function. There exists the need to determine a dose 
that will ensure a good compromise between control probability and complication probability.   
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Figure 1-1. NTCP/TCP curves.  
Curves for probability of tumor control and probability of complication, with dose [Gy] on the x-axis and probability on the y-
axis. Both curves show a sigmoidal relationship between the probability of toxicity and the dose. Optimal radiation therapy 
compromises between these two curves. 
 
Currently, these toxicity models are based on planned dose. However, Velec et al (2012), Wong 
et al (2017), and Reese et al (2011)  showed that delivered dose is not equivalent to planned dose 
[25,36,37]. The field needs to accumulate radiation dose during treatment and develop new 
toxicity models based on accumulated dose. With the recent advances in image-guided radiation 
therapy, this is now theoretically possible.   
 
There are a limited number of studies that describe toxicity to the stomach due to radiation, 
separately from the small bowel. One study [38] found that 40.5Gy after chemotherapy and 
steroids led to 4% of patients developing acute nausea of grade 3 or higher. A randomized study 
[39] found that a single fraction of 8Gy to the lower hemi-body led to toxicity rates of 6-66% for 
moderate to severe nausea, depending on the type of chemotherapy. Complications in the small 
bowel as a response to radiation therapy include diarrhea, fistula, perforation, ulcers, obstruction, 
and constriction. One study [40] showed that cervical cancer patients had an increase in toxicity 
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of the small bowel with the addition of chemotherapy to 45Gy radiation therapy. A 5% toxicity 
rate was observed for those treated with radiation therapy alone, and a 14% toxicity rate was 
observed for those also treated with chemotherapy. The limited data for toxicity of gastro-
intestinal organs receiving dose during radiation therapy leads to the need to develop new, more 
specific, and more accurate toxicity models for these organs.  
 
Deasy et al [32] indicated in a Qualitative Analyses of Normal Tissue Effects in the Clinic 
(QUANTEC) Organ-Specific Paper that in order to improve HN patient toxicity due to radiation 
therapy, it must be determined if anatomical variations occur in the salivary glands during 
radiation therapy, and if shrinkage of the parotid glands should be incorporated in prediction 
models. They stated that the main goal is to validate accurate prediction models for the function 
of the salivary glands.  
 
The importance of the accurate accumulation of dose to normal tissues for improved 
understanding of toxicity was highlighted in a QUANTEC Vision paper by Jaffray et al [41] in 
2010, stating that creating accurate distributions of the accumulated dose for the tumor and 
normal tissue was clinically feasible. In order to make this process regular in radiation therapy, 
deformable image registration, dose accumulation, and techniques to estimate accumulated dose 
uncertainties must be further developed.  
 
1.3.4 Liver cancer toxicities 
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Radiation-induced liver disease (RILD) can occur just weeks after completion of radiation 
therapy, or months to years later. RILD is the most common significant toxicity that occurs due 
to EBRT and is a major limitation due to its association with high mortality rates. Symptoms of 
RILD include abdominal pain, hepatomegaly, fatigue, anicteric ascites, and abdominal swelling 
[42]. Although the characteristics of RILD are well understood, the pathogenesis remains 
unclear. RILD can lead to liver failure and has a 10-20% mortality rate [43].  
 
Before technological advances of the early 2000s, radiation treatments for liver cancer consisted 
of irradiation of the entire liver. In these treatments, RILD rates were 5% for doses up to 30Gy, 
10-13% for doses of 30-35Gy, and 44% for doses above 35Gy [44,45]. For daily 2Gy/fraction 
radiation therapy, the TD5/5, or the dose at which there is a 5% risk at 5 years, for RILD is 
≤28Gy for primary liver cancer and ≤30Gy for liver metastases, which are the tolerance doses for 
whole liver irradiation [44]. These doses are considered palliative, which means that the dose 
aims to slow tumor growth, shrink the tumor, or control symptoms, and not necessarily to cure 
the cancer.       
 
The liver is a parallel organ, meaning that the damage to one region of the liver does not indicate 
the loss of function to the entire organ. NTCP models have been developed to describe the partial 
volume tolerance of the liver to radiation, where the toxicity being modeled is RILD. These 
models are used to design radiation treatments for the liver that minimize risk of RILD. The 
Lyman NTCP curve (1985) [35] models the relationship between NTCP risk and the dose of 
uniform partial liver irradiation as sigmoidal. The effective volume, Veff, is typically used in the 
Lyman NTCP model and refers to the uniformly irradiated volume (Eq. 1-3):  
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 𝑉𝑒𝑓𝑓 =∑𝑣𝑖(𝐷𝑖/𝐷𝑟𝑒𝑓)
1/𝑛
𝑖
 (1-3) 
   
where vi is the volume, Di is the dose, and Dref is the reference dose, and n determines volume 
dependence. For normal tissue, n > 0. For a parallel organ, where the dose metric is the mean 
dose, n = 1. For a serial organ, where the dose metric is the maximum dose, 1 > n > 0. A Lyman 
NTCP model has been established [46] based on the correlation between mean liver dose and the 
risk of RILD for a series of 203 patients.  The study also demonstrated that doses over 100Gy 
could potentially be delivered to small regions of the liver (Veff < 30%) with a resulting NTCP 
risk under 5%.  
 
1.3.5 Head and neck cancer toxicities 
 
Toxicity due to radiation treatment of HN cancer includes mucositis, nausea, vomiting, cough, 
dehydration, fatigue, stomatitis, weight loss, infection, hemorrhage and many other adverse 
effects [47]. A common side effect that can severely decrease the quality of life (QoL) for HN 
cancer patients is xerostomia (dry mouth). A major indicator of xerostomia during HN radiation 
therapy is severe radiation damage to the salivary glands [48]. 
 
Xerostomia risk can be decreased with the reduction of parotid gland volume receiving high 
dose. Using IMRT, at least one parotid gland can be spared in certain patients. The high dose is 
only delivered to the region of the parotid gland in close proximity to the tumor, and the 
remaining parotid gland receives a much lower dose [48,49]. Several studies [50-54] have shown 
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that salivary function in the parotid glands can be conserved when IMRT is used. Additionally, 
several prospective trials have shown that IMRT can reduce xerostomia risk while still 
controlling the tumor [29,55-58].  
 
Several uncertainties in toxicity modeling exist. NTCP models are historic population models 
based on toxicity data from thousands of patients. Because biological differences exist between 
patients, there is some error in the models. Xerostomia is determined by salivary flow, which is 
assessed based on the collection of patient saliva. One method consists of having the patient 
swallow, instructing them not to move or swallow, and then collecting and measuring their saliva 
[59]. Another methods consists of having the patient chew gum at a certain pace, and instructing 
them to “Spit out, keep chewing” every minute [59]. These methods are also not exact and can 
potentially add uncertainty to the models. Additionally, toxicity grading is not exact and 
potentially adds uncertainty to the models. Xerostomia is rated from grade 1 through grade 3, 
where grade 1 xerostomia indicates that the patient is symptomatic with dry/thick saliva and 
without significant alteration to the diet (unstimulated salivary flow > 0.2 ml/min), grade 2 
indicates that the patient is symptomatic and that their oral intake is altered (unstimulated 
salivary flow 0.1 to 0.2 ml/min), and grade 3 indicates that the patients cannot adequately ingest 
orally (unstimulated salivary flow < 0.1 ml/min) [60]. With the advent of functional imaging, 
more quantitative data can be generated for more accurate grading. Uncertainty in the dose also 
adds uncertainty to NTCP models. Resolving these uncertainties using accumulated dose may 
lead to more accurate toxicity modeling, and for the correction of biological uncertainties in 
these models.    
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1.3.6 Dose accumulation for liver 
 
Lujan  [61] applied convolutional methods to account for uncertainties from patient setup and 
organ motion of the liver due to breathing. Eq. 1-4 shows his derived dose distribution that 
includes breathing motion.   
 
 ?̅?(𝑥, 𝑦, 𝑧) =  ∫𝐷0(𝑥, 𝑦, 𝑧
′)𝑝𝑜𝑚(𝑧
′ − 𝑧)𝑑𝑧′ (1-4) 
 
Where ?̅?(𝑥, 𝑦, 𝑧) represents, for point x, y, z, the new dose distribution,  𝐷0(𝑥, 𝑦, 𝑧
′) represents, 
for point x, y, z’, the original dose distribution, and 𝑝𝑜𝑚(𝑧
′ − 𝑧) is a probability distribution 
function describing breathing motion. Breathing motion was also fit to a mathematical model,  
 
 𝑧(𝑡) = 𝑧0 − 𝑏𝑐𝑜𝑠
2𝑛(
𝜋𝑡
𝜏
− 𝜙) (1-5) 
 
Where 𝑧0 represents the exhale position, b represents the motion amplitude, 𝑧0 − 𝑏 represents the 
inhale position, 𝜏 represents the breathing period cycle, n represents the model shape, and 𝜙 
represents the breathing cycle starting phase. Eq. 1-6 shows his derived dose distribution that 
includes patient setup uncertainties.  
 
?̅?(𝑥, 𝑦, 𝑧) =  ∭𝐷0(𝑥
′, 𝑦′, 𝑧′)𝑁(𝑥′ − 𝑥, 𝑦′ − 𝑥, 𝑧′ − 𝑥)𝑑𝑥′𝑑𝑦′𝑑𝑧′ (1-6) 
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Where ?̅?(𝑥, 𝑦, 𝑧) represents, for point x, y, z, the average dose incorporating uncertainties, 
𝐷0(𝑥
′, 𝑦′, 𝑧′) represents, for point x’, y’, z’, the static dose, 𝑁(𝑥′ − 𝑥, 𝑦′ − 𝑥, 𝑧′ − 𝑥) represents 
the normalized PDF for each direction. His work demonstrated that convolutional methods could 
predict the delivered dose distribution for any amount of radiation therapy fractions. His work 
also demonstrated that for an infinite number of fractions, the delivered dose distribution could 
be calculated with convolutional techniques. Due to the finite number of fractions during true 
radiation treatment, the patient may receive a different dose distribution than the average. A 
method was then developed to calculate the standard deviation for any point in the patient. The 
finite-fractioned treatment was then compared to the convolutional method. The convolutional 
method included breathing motion and patient setup error in a dose distribution and results were 
validated with Monte Carlo methods. This work demonstrated that breathing motion and patient 
setup uncertainties should be convolved with dose functions for liver radiation therapy.    
 
Brock [62] studied two deformable image registration methods to describe deformation of the 
liver during radiation therapy. The first method involved finite element analysis (FEA), which 
was based on a linear-elastic mechanical liver model. The second method involved mutual-
information based registration, and consisted of a geometric liver model. The accuracy of the 
mutual-information based alignment was 1.0, 1.2, and 1.44 mm for the left-right, anterior-
posterior, and inferior-superior directions. One inhale CT and one exhale CT was used to include 
breathing deformation in dose calculations. The dose delivered to the liver with breathing 
deformation was summed using the transformation from the deformable  alignment. Eq. 1-7 
shows the total dose delivered for a voxel with initial position x, y, z during breathing.   
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𝐷(𝑥, 𝑦, 𝑧) =  ∑ [
𝐷𝜙
𝐸(𝑥 + 𝜙𝛥𝑥 , 𝑦 + 𝜙𝛥𝑦, 𝑧 + 𝜙𝛥𝑧)(1 − 𝜙) +
𝐷𝜙
1(𝑥 + 𝜙𝛥𝑥, 𝑦 + 𝜙𝛥𝑦, 𝑧 + 𝜙𝛥𝑧)𝜙
]
1
𝜙=0
𝑇∅ (1-7) 
 
 
Where 𝛥𝑥 , 𝛥𝑥 , and 𝛥𝑥 represent the transformation that resulted from the mutual-information 
based alignment in each direction, DE  and D1  represent the doses from the exhale and inhale 
dose grids, respectively, 𝜙 represents the breathing phase, and 𝑇∅ represents the time weighting 
based on 𝜙. Static dose calculations were compared to the dose calculations that included 
deformation, in order to determine the effect of deformation. Based on this comparison, 33% of 
the patients included in the study had prescribed dose changes exceeding one treatment fraction. 
For tumors residing in the inferior and superior regions of the liver, the effect of deformation was 
the greatest.  
 
Later work by Brock et al [63] involved the development of a biomechanical model-based 
deformation image registration algorithm, Morfeus. This method models the deformation of 
individual organs by assigning linear elastic properties to each of them and applying boundary 
conditions on their surfaces. This method was evaluated for the lung, liver, spleen, external 
surface, stomach, and kidneys. Velec [64] used Morfeus to track the tumor and surrounding 
normal tissue during radiation therapy for liver cancer. Dose accumulation for the liver cancer 
patients was enabled by modeling their daily anatomic variations. Estimates of delivered dose 
were improved by dose accumulation. Delivered dose reconstruction indicated substantial 
deviations (>5%) between planned and delivered dose for 70% of the patients included in the 
study. These uncertainties ranged between -42% and 8% for normal tissue and -15% and 5% for 
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tumors. In order to minimize the error in targeting the tumor as well as deviations between 
planned and delivered dose, image-guidance with respiratory-correlated imaging was used. This 
work also included the development of a treatment strategy that reduced breathing motion impact 
and employed a margin that accounted for deformation of the liver. The applied margin 
decreased the clinical margin by 38% and allowed for a 9% dose increase to the tumor while 
maintaining the toxicity risk to the surrounding normal tissue. The substantial deviations 
between planned and accumulated dose observed in this study indicate the need for improved 
toxicity models, based on accumulated dose.  
 
1.3.7 Dose accumulation and adaptive radiation therapy for head and neck cancer  
 
Treating HN patients with IMRT leads to sharp dose gradients, which can potentially cause 
greater inaccuracies in the dose distribution than standard techniques in the case of patient 
positioning errors and anatomical changes. Image-guided radiation therapy (IGRT) techniques 
can provide 3D images of the patient during radiation therapy, allowing for corrections in tumor 
position for more accurate radiation therapy.  
 
Several studies have investigated the volumetric changes for HN patients undergoing radiation 
therapy, exploring tumor shrinkage and weight loss. Barker et al [31] studied 14 patients with in-
room imaging (CT-on-rails) acquired three times per week. Rigid image registration was used to 
compare the daily images with the planning image. The tumor and parotid glands shrunk 1.8% 
and 0.6%, respectively, for each day of treatment. Geets et al [65] investigated the volumetric 
change for 10 patients using CT scans taken four times throughout treatment. The per-treatment 
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images were rigidly registered to the planning image. The tumor shrunk 65.5% after delivery of 
45Gy (mean dose). Han et al [66] used daily imaging (helical megavoltage CT) rigidly registered 
to the planning image for five patients and found 1.1% shrinkage in the parotid glands per day of 
treatment, with an overall average change from 20.5cm3 to 13.2cm3. Hansen et al [67] acquired 
CT scans after delivery of 38Gy for 13 patients, rigidly aligned the images to the planning 
images, and found no volumetric change in the tumor, but 15.6% shrinkage in the right parotid 
gland and 21.5% shrinkage in the left parotid gland. Robar et al [68] acquired weekly CTs for 15 
patients, rigidly aligned them to the planning images, and found shrinkage in the superficial lobe 
of the parotid glands of 4.9% per week. 
 
Osorio et al [69] acquired CT images after 46Gy was delivered to 10 patients, registered the per-
treatment CT to the planning image using deformable image registration, and found 25% 
shrinkage in the tumor, 17% shrinkage in the parotid glands, and 20% shrinkage in the 
submandibular glands after 46Gy. Castadot [70] acquired CT scans four times during treatment 
for 10 patients, used deformable image registration to align them with the planning images, and 
found tumor shrinkage of 3.2% per treatment day and parotid gland shrinkage of 0.9% per 
treatment day. 
 
Several studies have investigated the impact that these anatomical variations have on the planned 
radiation dose, based on image-guided radiation therapy (IGRT) methods. Hansen et al [67] 
acquired CT scans after 38Gy was delivered to 13 patients and rigidly registered the per-
treatment CTs to the planning images. The parotid gland V26Gy (volume of the parotid glands that 
received at least 26Gy) increased by 10.9%, and the mandible V60Gy increased by 7.2%. This 
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study also found that replanning lead to a significant improvement in the maximum dose to the 
spinal cord and brainstem, mean dose and V26Gy to the right parotid gland, and maximum dose 
and V60Gy to the mandible. Robar et al [68] studied 15 patients with weekly CT scans and found 
that the mean dose and V26Gy increased 2.6% and 3.5% in the left parotid gland and 0.2% and 
0.3% in the right parotid gland. Han et al [66] used daily helical megavoltage CTs and rigid 
registration for 5 patients and found an increase in the mean dose to the parotid gland from 0.83 
to 1.42Gy.  
 
O’Daniel et al [71]  studied 11 patients with in-room imaging (CT-on-rails) acquired two times 
per week. Deformable image registration was used to register the per-treatment images to the 
planning CT. A median dose increase of 1Gy to the parotid glands was observed. This study also 
found that the cumulative dose to the parotid gland was higher than the planned dose in the case 
that IGRT was not used during daily patient setup. Lee et al [72] used daily helical megavoltage 
CT and deformable image registration and found that the daily mean dose delivered to the 
parotid gland deviated from the planned dose by 15%. The total accumulated mean dose to the 
parotid gland was 32.7Gy, while the total planned mean dose was 29.7Gy. This study also found 
a relationship between weight loss of the patient and greater mean dose to their parotid glands. 
Castadot [70] used CT scans taken four times throughout treatment for 10 patients and aligned 
them to the planning image using deformable image registration. This study found that the 
parotid glands were planned to a mean dose of 17.9Gy, but in actuality received 18.7Gy, and that 
the submandibular glands were planned to a mean dose of 51.9Gy, but in actuality received 
52.8Gy. 
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Kong et al [73] showed the relationship between salivary flow in HN cancer patients and the 
mean dose to their parotid glands. The study demonstrated that even for parotid glands that 
received no dose, there was still no salivary flow for some patients. One potential explanation for 
this observation is that deviations between the planned and delivered dose existed for these 
patients. While their parotid glands were planned to receive no dose, they received some dose 
due to anatomical changes that may have occurred during radiation, leading to xerostomia. 
Toxicity models for radiation treatment are based on the planned mean dose to the entire gland, 
and may not be accurate. To date, there is a need to develop new models, as well as to assess the 
uncertainties and increase the accuracy of dose accumulation in these models.  
 
 Goals and Organization of this thesis 
 
Adaptive radiation therapy aims to limit the discrepancies between planned and delivered 
radiation dose with replanning. Adaptive radiation therapy relies on accurate dose accumulation, 
which is based on accurate anatomical modeling. Dose accumulation based on accurate 
anatomical modeling can potentially translate to more accurate toxicity models. This thesis 
focuses on modeling the anatomical changes of patients undergoing radiation therapy and the 
potential clinical impact of the discrepancies between planned and delivered dose that these 
changes cause, for the abdominal region and the HN region.  
 
There are three major aims included in this thesis work: i) to improve the understanding of 
toxicity by quantifying deviations between accumulated and planned dose in NTCP models, ii) to 
develop predictive models for treatment replanning decisions, and iii) to develop biomechanical 
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models of dose response in order to improve toxicity prediction models. This thesis includes four 
main chapters, based on the major aims of this dissertation.  
 
Chapter 3 investigates the potential clinical impacts of building luminal NTCP models based on 
accumulated dose rather than planned dose. NTCP models were simulated based on accumulated 
dose using statistical modeling for patients treated with liver SBRT. It was hypothesized that 
using accumulated dose data from DIR and statistical modeling to simulate new toxicity models 
for the duodenum and stomach will result in potentially clinically significant differences from 
the standard model. The goal of the first aim was to quantify the potential clinical impact of 
developing NTCP curves based on accumulated dose rather than the standard, planned dose 
model. Luminal (tubular) GI structures were chosen for this study because these are often 
radiation dose-limiting organs.  
 
Chapter 4 describes the development of predictive models for treatment replanning decisions in 
HN treatments. The need to replan is frequent in the HN site, as weight loss and tumor response 
can cause potentially clinically significant deviations between delivered and planned dose. Using 
these findings, we hypothesized that a dose deviation threshold could be applied to build a model 
that predicts, with 100% sensitivity, the need to replan a patient to avoid clinically relevant dose 
deviations. The goal of this aim was to develop and validate a predictive model to determine 
selection criteria where HN patients will need adaptive replanning by mid-treatment to avoid 
substantial deviations in their accumulated dose. 
 
Chapter 5 investigates an optimal technique to resolve the varying angles of neck flexion 
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between images acquired during HN radiation therapy. A biomechanical model-based DIR 
algorithm with boundary conditions on bony anatomy is proposed to accurately account for neck 
flexion of HN patients.   
 
Chapter 6 examines the development of biomechanical models of dose response of the parotid 
glands to improve toxicity prediction models. The dose metric used for assessment of the parotid 
glands is mean dose, and this metric is used as the basis for toxicity modeling. However, recent 
small animal studies show that there may be a stronger correlation between dose to substructures 
of the parotid glands and toxicity [74]. In order to establish the relationship between the 
substructure dose and parotid gland toxicity, the dose to the substructures must be evaluated. The 
spatial response of the parotid glands to radiation is expressed using thermal expansion 
coefficients to apply dose-based boundary conditions. The volumetric change in the parotid 
glands during radiation treatment is dramatic compared to other organs, making this an exciting 
site to evaluate the dose-response. 
 
Chapter 7 is the concluding chapter that discusses the potential clinical impact and possibility for 
future studies based on this work.
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Chapter 2. Background 
Approximately 40% of the US population will develop cancer during their lives[75], and 50% of 
these patients are treated with radiation therapy as part of their cancer treatment. Radiation 
therapy is part of a comprehensive treatment plan that may also include surgery or 
chemotherapy. Radiation is used to treat cancer by delivering high doses of radiation to the 
tumor in the form of x-rays, gamma rays, or charged particles. Radiation destroys cancer cells 
through DNA damage, which can be direct or indirect. Once DNA is damaged, those cells can no 
longer divide or survive. It is therefore crucial to limit the dose to normal tissue. For biological 
reasons the treatment is often fractionated, e.g. delivered over several treatment sessions.  
 
 Radiation Therapy Workflow  
 
Once patients are diagnosed with cancer and referred for radiation therapy, they undergo a 
treatment workflow that includes imaging in radiation oncology, radiation treatment planning, 
dose delivery over a series of fractions, and imaging for patient follow up (Fig. 1.1). Although 
radiation therapy encompasses external beam radiation therapy (EBRT) and brachytherapy, this 
dissertation will focus on EBRT, which is the most common method of radiation treatment.   
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Figure 2-1. Radiation therapy workflow.  
Images from left to right: treatment imaging, treatment planning, dose delivery, and follow-up imaging. Linear 
accelerator: Clinac iX System, Varian Medical Systems, Palo Alto, CA.  
 
2.1.1 Computed Tomography  
 
The standard imaging modality for treatment planning is computed tomography (CT). CT 
scanners consist of a detector opposite of a kV x-ray tube, which rotates around the patient. 
Measurements are taken as the x-ray and detector rotates, which returns data for multiple x-ray 
projections through the patient. A cross-sectional image can then be reconstructed 
mathematically to represent tissue visually based on its estimated attenuation coefficients, known 
as CT numbers. CT numbers are referred to as Hounsfield Units (HU), which are calculated 
using Eq. 2-1, 
 
 𝐻𝑈 = 1000 ∗
𝜇 − 𝜇𝑤𝑎𝑡𝑒𝑟
𝜇𝑤𝑎𝑡𝑒𝑟
  (2-1) 
 
where µ represents the linear attenuation coefficient. Hounsfield units are dependent on the 
energy of the CT beam but generally range from -1,000 for air to -100 for fat to 0 for most tissue 
to 1,000 for bone. Electron density (electrons/cm^3) is needed in order to perform radiation dose 
calculations. Electron density is calculated using the CT number based on the linear correlation 
between CT numbers and attenuation coefficients. The calibration is performed by obtaining CT 
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images of phantoms with known electron densities, representing lung, muscle, and bone to 
enable the relationship between CT number and electron density to be established.        
The planning CT, or CT simulation as it is often referred to as, is the acquisition of a diagnostic 
CT image with the patient in the treatment position using an immobilization device. An example 
of an immobilization device used for brain and head and neck treatments is a mask (Fig. 1.2) that 
is designed to individually fit to the patient. The immobilization mask is a plastic mesh that is 
heated and formed to the patient’s head. Once the plastic returns to room temperature, it becomes 
rigid and is used to reproduce the position at CT simulation during each treatment delivery and 
aid in reducing patient movement during radiation delivery.  
 
 
 
Figure 2-2. Immobilization mask for head and neck (HN) radiation therapy.  
The material is heated, molded to the individual patients face, and cooled. The patient wears the mask during each 
fraction of radiation therapy to ensure that they are in the same position as they were during their planning scan.  
 
2.1.2 Radiation Treatment Planning 
 
Radiation treatment planning starts with the outlining of normal tissue and tumor on the planning 
CT. This outlining process is called contouring or tissue delineation. The radiation oncologist 
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contours the tumor (target volume) and then the organs at risk (OAR), which are normal tissues 
near the tumor. The target volumes defined in radiation oncology and recommended by the 
International Commission on Radiation Units and Measurements (ICRU) are the gross tumor 
volume (GTV), clinical target volume (CTV), internal target volume (ITV), and planning target 
volume (PTV). An example of these target volumes for a head and neck cancer patient can be 
seen in Fig. 1.3. The GTV consists of the tumor, including primary or metastatic disease, that is 
visible on all available images. The CTV includes the region around the visible tumor that may 
have microscopic disease, not visible on imaging. The ITV accounts for the CTV as well as size, 
shape, and positional uncertainties in the CTV. The PTV encompasses internal variations, which 
include CTV position, shape, and size, and external variations, which include beam and patient 
positioning [76]. Van Herk et al [77] developed a formula (Eq. 2-2) to calculate the PTV margin, 
M, necessary for the CTV to be covered by a minimum of 95% of the prescription dose for 90% 
of the population. Systematic errors, which are typically introduced during treatment planning 
and carried through treatment, cause shifts in the dose distribution (relative to the CTV). Random 
errors, which occur because of variations in day-to-day treatment, cause dose distribution 
blurring.  
 
 𝑀 = 2.5 𝛴 + 1.64(𝜎 − 𝜎𝑝)  (2-2) 
 
where 𝛴 represents the standard deviation for systematic errors, 𝜎𝑝 represents the width of the 
radiation beam’s penumbra, and 𝜎 is the sum of 𝜎𝑝
2and the squared standard deviation of the 
random errors. 
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Figure 2-3. Depiction of gross tumor volume (GTV), clinical target volume (CTV), and planning target volume 
(PTV). 
 
Following contour delineation, radiation parameters corresponding to the function of the linear 
accelerator, for example the number of beams, beam angle and fluence through a multileaf 
collimator, are optimized by the treatment planning software in order to obtain a 3D dose 
distribution. This dose distribution (Fig. 1.4) will aim for the target to receive the prescribed dose 
and for the dose to other structures to be as low as possible and not exceed given constraints.  
Advanced treatment delivery techniques have been developed to modulate the radiation, enabling 
improved sparing of normal tissue and targeting of the tumor.  These techniques include 
volumetric modulated arc therapy (VMAT), which is a radiation therapy technique in which 
delivery of radiation is entirely dynamic, and moves linearly between positions of the multi-leaf 
collimator (device composed of Tungsten leaves that move individually in and out of the particle 
beam path to block it) while the radiation beam is on with variable gantry speed and dose rate.  . 
 27 
VMAT also has the potential to offer additional advantages, such as reduced treatment delivery 
time compared with conventional static field intensity modulated radiotherapy (IMRT).  
 
IMRT is a traditional technique which involves non-uniform beam intensities and is normally 
delivered with treatment delivery equipment controlled by a computer. With IMRT, the patient 
can be treated from different directions with nonuniform beams that are optimized to spare 
normal tissue while delivering high radiation dose to the tumor. The TPS converts the beams into 
many beamlets and optimizes their weights or fluences. The intensities and weights of the 
beamlets can be adjusted to meet the requirements of the dose plan (inverse planning). Optimal 
intensity profiles are calculated using analytic or iterative methods on a computer. Analytic 
methods are done with mathematical techniques that invert the dose distribution with back 
projection algorithms. Iterative methods consist of iteratively adjusting the weights of the 
beamlets to minimize cost function value. The standard cost function is the least square function 
(Eq. 2-3).  
 
 𝐶𝑛 = [(
1
𝑁
)∑𝑊(𝑟)(𝐷0
𝑟
(𝑟) − 𝐷𝑛(𝑟))
2]
0.5
  (2-3) 
 
where 𝐶𝑛 represents the cost at iteration n, 𝑟 is a point in the patient, 𝐷0(𝑟) represents the 
optimal dose, 𝐷𝑛(𝑟) represents the calculated dose at that point, 𝑊(𝑟) represents the weight of 
the structures, and N represents the number of dose points. For the tumor, the root mean squared 
difference between the true dose and the prescription dose equals the cost. For the normal tissue, 
the root mean squared difference between the true dose and zero dose is the cost. The sum of the 
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normal tissue and tumor costs, based on their weights, determines the total cost. The goal of the 
optimization algorithm is to minimize the total cost for every iteration until the goal radiation 
dose is reached.  
 
In order to prevent errors during the radiation therapy process, quality assurance (QA) is 
performed. QA is a process completed by a team of medical physicists in order to ensure the 
safety of patients, and includes measuring dose with a phantom, which is made of a synthetic 
material that mimics human tissue and comparing the measurements with the calculations 
obtained from the treatment planning system. Before delivering VMAT to a patient, 
measurement-based QA is performed. This is often done using a  cylindrical acrylic phantom 
accompanied by an array of diode detectors that compare the measured and calculated doses 
[78]. The measurements are then assessed using both distance and accuracy metrics, referred to 
as a gamma analysis [79,80]. Most institutions use a 3%, 3 mm pass rate for 95% of the points 
[78].  When this cannot be achieved, the plan must be evaluated by the medical physicist to 
determine its suitability for patient treatment. 
 
To deliver radiation, the linear accelerator accelerates electrons, which then collide with a 
Tungsten target to generate high-energy x-rays through bremsstrahlung. A multileaf collimator, 
situated inside the head of the linear accelerator, shapes the radiation beam. Finally, the beam 
emerges from the gantry, which rotates around the patient accordingly. The patient lies on the 
treatment couch, which is also moveable in 3 translational directions and in special cases 
rotational axes as well. Based on gantry rotation and treatment couch movement, the radiation 
beam can deliver dose at any angle. Before treating the patient, the aforementioned parameters 
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must be designed in process called ‘treatment planning’, which is typically performed by a board 
certified dosimetrist, or in some clinics or in especially complex cases, a board-certified medical 
physicist.  
 
 
Figure 2-4. Optimized dose distribution on a HN CT scan.  
The red contour surrounds the target tissue (tumor) and refers to the high-dose region. The green contour surrounds 
the low-dose region, and the yellow and orange contours represent the medium-dose region. Dose distributions are 
optimized to limit dose to surrounding tissue while distributing the maximum dose to the tumor. 
 
2.1.3 In-Room Imaging/Cone-Beam Computed Tomography  
 
The radiation dose prescribed by the radiation oncologist is typically delivered over a series of 
days, or fractions of smaller doses, which are delivered over the course of radiation therapy. The 
number of fractions varies depending on the treatment strategy. Before dose delivery at each 
fraction, the patient is positioned in the immobilization device, with the goal to reproduce their 
position from the CT simulation. Traditionally, the patient is repositioned according to external 
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landmarks such as skin markers. Portal imaging, which acquires images with the MV radiation 
beam from the linear accelerator, allows for the alignment of bony anatomy and some soft tissue 
structures (e.g. the lung diaphragm interface). While this technique is more reliable than skin 
markers for positioning, it offers limited soft tissue targeting. A recent and widely adopted 
advancement is the addition of a kV x-ray tube mounted 90 degrees from the MV radiation 
beam, enabling cone-beam CT (CBCT) acquisition in the treatment room (Fig. 1.6). The CBCT, 
as its name indicates, consists of a cone beam of x-rays contrary to a fan beam for the CT. CBCT 
imaging allows the visualization of bony anatomy and soft tissue in 3D, and can be useful for 
anatomical localization in the head and neck, abdomen, and pelvis regions (Fig 1.5).  
 
 
Figure 2-5. Head and neck (HN) 3D cone-beam CT (CBCT).  
These images are acquired at each fraction of radiation therapy to align the patient with their initial position.  
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Figure 2-6. Linear accelerator with cone-beam computed tomography (CBCT).  
True Beam, Varian Medical Systems, Palo Alto, CA.  
 
2.1.4 Rigid Registration 
 
Image registration involves finding the geometric transformation between corresponding 
anatomical points in two images. These two images are referred to as the reference dataset and 
the target dataset. Image registration in radiation oncology is used for image-guided treatment, 
contour propagation, dose accumulation, and integrating multi-modality images such as CT, 
magnetic resonance imaging (MRI), and positron-emission tomography (PET). The CBCT 
acquired just before radiation therapy allows for proper repositioning of the patient to the 
radiation beam by shifting and possibly slightly rotating the treatment couch. The applied 
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translation and rotation can be visualized with image fusion tools after the rigid image 
registration is calculated between the CBCT and the CT. Rigid image registration aims to 
optimize six transformation parameters: a translation in the superior-inferior, left-right, and 
anterior-posterior directions, and a rotation around each axis relative to the coordinate system 
origin. These three translations and three rotations are applied to the target image in order to 
align it to the reference image. This rigid transformation can then be applied to the patient to be 
accurately positioned prior to treatment. The optimal alignment prioritizes the alignment of a 
reference structure, such as a specific normal tissue or the tumor, or as a compromise between 
the alignments of different structures. An example alignment between the two images can be 
shown in a fused image (Fig. 1.7).  
 
 
Figure 2-7. Rigid alignment of CT images.  
A planning CT (left) and pre-fraction CBCT (middle) are rigidly aligned. A fused image (right) can be generated 
based on rigid registration. The purple represents the CT and the green represents the CBCT. 
 
2.1.5 Radiation Dose Calculation 
 
The International Commission on Radiation Units and Measurements (ICRU) recommends a 
combined dose uncertainty below 5% [76] . As dose calculations from the TPS, machine 
calibration, and patient setup carry additional uncertainty, the dose calculation algorithm itself 
must estimate the dose distribution within an accuracy of 3%. The most accurate dose calculation 
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method is Monte Carlo, which simulates photon and electron transport to model the beam [81] . 
This method involves determining the history of each particle using a random number generator. 
The dose distribution is generated by combining the energy deposited by each particle. Monte 
Carlo methods for dose calculations are computationally expensive and currently not practical in 
the clinic, however they are used as benchmark calculations for other methods [82] . The other 
common dose calculation algorithms can be classified under two types. One type involves 
models based on equivalent tissue-air ratio (ETAR) [83] or the scaling of equivalent path length 
(EPL) [84] for inhomogeneity corrections. These techniques do not model the differentiations in 
lateral electron transport. The second type is based on convolution techniques, where 
inhomogeneities are managed with EPL correction or scaled kernels. The lateral transport of 
electrons is approximated for these techniques. The first type does not result in accurate dose 
distribution calculations in patients, but can be used in some TPSs to give an estimate of the 
absorbed dose. The second type results in dose calculations near the accuracy of Monte Carlo 
simulations, but have the benefit of being less time-consuming.   
 
 
2.1.6 Dose calculation algorithms  
 
The dose calculation algorithms used in this thesis were based on the treatment planning system 
used for those patients. One treatment planning system was Pinnacle (Philips, U.S.A). The dose 
calculation algorithm implemented in Pinnacle is the collapsed cone convolution (CCC) method. 
The CCC method employs angular discretization of the kernel to allow energy transport and 
deposition. The following equation describes the energy deposition per radial distance based on 
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this method where the dose fractions are scaled for the point kernel ℎ𝜌𝑜, for a homogeneous 
medium with a mass density of 𝜌𝑜: 
 
 ∬
ℎ𝜌𝑜
𝜌
(𝑟, 𝛺)𝑟2𝑑2𝛺 = 𝐴𝛺𝑖𝑒
−𝑎
𝛺𝑖
𝑟
+ 𝐵𝛺𝑖𝑒
−𝑏
𝛺𝑖
𝑟
 (2-4) 
 
where 𝛺𝑖 is a discrete angular sector (cone), ρ is the density, r is the radius, and A and B are 
elements. Due to interactions as the lower cone’s vertex, energy meant to be deposited in voxel 
B’ is deposited in voxel B, as a consequence of using the CCC approximation. Although the 
displacement increases with distance, the first scatter fraction decreases as the distance increases, 
which allows for the conservation of total energy deposition. Displacement errors occur within 
voxels, as most of the energy is deposited where it is released. It can be noted from this equation 
that due to the cone’s increasing cross section, the radius’s inverse square cancels as the radius 
increases. The terma distribution, where terma can be defined as the total energy released per 
mass [85], is convolved with the angular discretized kernel. The cones are essentially collapsed 
into their axes, as we approximate the energy release to be rectilinearly deposited in the volume 
elements of the axis. To represent the cone axes, a transport line lattice is created to incorporate 
the irradiate volume so every calculation voxel is intersected. For all discrete directions of the 
collapsed kernel, there must be a parallel subset of lines. We can express analytically the energy 
transport along a line, because the kernel is described exponentially. The resulting recursive 
formulas need to be evaluated just once for each voxel on the line. During this recursion, kernel 
scaling for heterogeneities is completed for scatter and primary dose kernels, and the recursion 
pass each voxel a minimum of one time for each direction. In the case that the points are 
individually calculated, the amount of operations is proportional to MN4, where M represents the 
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number of angular bins. The CCC method has been compared with dose distributions generated 
by Monto Carlo simulations with generally satisfactory results. However, in off-axis dose 
profiles, the differences between CCC and Monte Carlo increase. In low density regions, 
differences of up to 10% have been observed [86]. 
 
Another treatment planning system used for the studies described in this thesis was Eclipse 
(Varian Medical Systems, Palo Alto, CA). The dose calculation algorithm implemented in 
Eclipse is the analytic anisotropic algorithm (AAA). This superposition algorithm is similar to a 
pencil beam algorithm and represents patient scatter and bream properties with a multiple-source 
model. Small beamlets (β) make up the clinical beams. The calculation grid size is related to the 
beta cross sections. The AAA method assumes that the dose at a point is the sum of the doses of 
a depth and lateral part, perpendicular to the beamlet direction. The depth dependent functions of 
the convolution are calculated on the beamlet’s central fan line. The scatter kernels that model 
energy transport are discretized in 16 directions (lateral). Equation (Eq. 2-5) shows the absorbed 
energy (𝐸𝑖,𝛽) for a particle (i) and area β, 
 
 𝐸𝑖,𝛽(𝜉, 𝑧) = 𝛷𝑖,𝛽𝐼𝑖,𝛽(𝑧)∫𝐾𝑖,𝛽(𝑢 − 𝑥
′, 𝜐 − 𝑦′, 𝑧′)𝑑𝑢𝑑𝜐 (2-5) 
 
where an equivalent path is represented by 𝜉, the depth is represented by z, the fluence is 
represented by 𝛷𝑖,𝛽, the attenuation function is represented by 𝐼𝑖,𝛽(𝑧), and the lateral energy 
transport is represented by 𝐾𝑖,𝛽. Scaling the beamlet’s attenuation function allows for the 
heterogeneities of the tissue to be incorporated. The AAA algorithm reduces computational time 
with analytical convolution, which is made possible by using analytical functions only [87]. Two 
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previous studies [87,88] showed that the deviations between CCC, AAA, and Monte Carlo 
algorithms are within 5% of Dmax for clinical scenarios.   
 
As these algorithms are not 100% accurate, the estimated deviations due to patient motion 
explored in this thesis will be affected. The greatest errors within errors exist near the photon 
beam edges, as the spatial derivatives are largest in these regions. While Monte Carlo dose 
calculation algorithms are known to perform the most accurate dose calculations, they are time 
consuming and computationally expensive, and the CCC and AAA methods are known to result 
in dose calculations within an acceptable margin of error in the clinic. Dose calculation errors 
can be greatest in regions of high geometric complexity, such as the head and neck region. One 
study [89] compared the accuracy of a finite size pencil beam algorithm with EPL 
inhomogeneity correction with a Monte Carlo algorithm. Statistical significance was not 
observed for the mean and maximum doses to the GTVs when comparing the pencil beam and 
Monte Carlo method. Differences in the D50, mean dose, and maximum dose were not 
statistically significant between the two methods for the spinal cord and mandible. Differences in 
the D50, mean dose, and maximum dose were 4%, 4%, and 1%, respectively for the parotid 
glands. Additionally, a 6% difference was observed in the volume that received over 25 Gy, 
V25. Another study [90] used ArcCHECK to test the 3D gamma passing rate for three dose 
calculation algorithms, using the 3 mm/3% criteria. The planned dose was compared to the 
measured dose for a pencil beam algorithm, a CCC algorithm, and a Monte Carlo algorithm. For 
the pencil beam algorithm, a 91.75±9.12% passing rate was observed. For the CCC algorithm, a 
93.12±7.75% passing rate was observed. For the Monte Carlo algorithm, a 94.52±5.85% passing 
rate was observed. 
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Recalculation of the daily dose distribution (Fig. 1.8) can be done using CBCT. This dose 
calculation is more challenging than on the planning CT due to the limited field of view (FOV) 
and to artifacts. CBCT artifacts are caused by inconsistencies between the physical imaging 
process and mathematical modeling. Artifacts are evident when the CT numbers in the 
reconstructed image are inconsistent with the attenuation coefficients in the tissue being imaged.  
Examples of artifacts that occur for CBCT are shadowing and scattering effects. Artifacts cause 
contour uncertainty as tissue boundaries can be unclear depending on the location of the artifact.  
However, previous work [91] has demonstrated that dose can be calculated on the CBCT within 
an accuracy of 2% (within a specified region) compared to calculations on the CT. The dose 
distribution allows for the delivered dose assessment during the treatment fraction to the target 
and OAR.  
 
 
Figure 2-8. Delivered dose distribution on a head and neck (HN) cone-beam computed tomography (CBCT).  
The red refers to the high dose region, the yellow refers to a moderate dose region, and the green and blue refer to 
low dose regions. The high dose region is sculpted around the tumor.   
 
 Accounting for Anatomical Variations  
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A leading cause in the uncertainty in the delivered dose to the patient is anatomical variation 
between fractions that occur over the course of treatment. Anatomical variation can be due to 
patient positioning, physiological processes (e.g. digestion, breathing, etc) weight loss, or 
volumetric changes of normal and tumor tissue due to radiation. When tumor shrinkage and 
other anatomical variations occur, it becomes challenging to determine if the dose delivered to 
that structure is consistent with the planned dose (Fig. 1.9). Velec et al [25] demonstrated that 
dose differences to the liver could exceed 5%. Recent studies have also been conducted to show 
the differences between planned and delivered dose for head and neck cancer, including 
Heukelom et al [92], who demonstrated that deviations of >3% in normal tissue complication 
probability (NTCP) between planned an delivered dose occur in 25% of head and neck patients. 
Deformable image registration (DIR) improves our ability to quantify discrepancies between 
planned and delivered dose. Quantification of these discrepancies allows investigation into new 
replanning strategies.  
 
 
Figure 2-9. Planning CT (left) and mid-treatment CBCT (right) with the same contours overlaid.  
The tumor contour and high dose region is delineated in red and no longer fits around the target tissue on the mid-
treatment CT. 
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2.2.1 Deformable Image Registration  
 
While rigid registration involves translation and rotation in all directions, DIR allows more 
degrees of freedom by allowing a spatially variant transformation. DIR algorithms are 
considered parametric when the transform is defined by a limited number of parameters, for 
example, when using B-spline functions [93]. DIR algorithms are considered non-parametric 
when the voxel displacements are independently calculated and regularized in an iterative 
process, for example, in the Demons algorithm [94]. All DIR algorithms provide a dense 
deformation vector field (DVF), i.e., a displacement for each voxel of the reference image. Since 
there exists a displacement vector for each voxel in the source image, the number of degrees of 
freedom can be up to three times the number of voxels in the source image. A regularization 
function constrains the spatially variant vector fields to establish that the transformation is 
realistic anatomically. The regularization function allows for a smooth deformation field. 
 
The deformation between the CBCT and the planning CT must be calculated to in order to align 
images. Accurate alignment of images allows for the calculation of dose accumulated by 
different structures and eventually to decide if re-planning is necessary. Calculating the 
deformation between the CBCT and CT can be done with DIR which provides a DVF that maps 
each voxel of the planning CT onto the CBCT.  
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Figure 2-10. Deformation field obtained with a DIR algorithm that can be used to spatially align images.  
The purple and green each represent different images.  
 
Registration metrics are used to assess how well two images are aligned. DIR is the optimization 
process that provides the transformation (DVF) that will maximize or minimize the registration 
metric. Two main categories of DIR are used in the clinic and for research. The most common 
DIR techniques used clinically are intensity-based, which use functions of the image intensities 
as similarity metrics such as the following methods.  
 
Sum of Squared Differences  
In the sum of squared differences (SSD) approach, the secondary image is transformed to the 
primary image to minimize the SSD (Eq. 2-6):   
 
 𝑆𝑆𝐷(𝐼1, 𝐼2) = ∑(𝐼1(𝑥) − 𝐼2(𝑥))
2
𝑥∈𝛺
 (2-6) 
 
where all voxels x within an image grid 𝛺 are considered. The method is based on the intensity 
of a voxel in the primary image (𝐼1) corresponding to the intensity of a voxel in the secondary 
image (𝐼2). This method is inexpensive in computing time, and is only applicable in cases where 
both images are of the same modality.  
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Cross-Correlation 
Cross-correlation (CC) is applicable for the case that there is a linear relationship between the 
two images [95]: 
 𝐶𝐶(𝐼1, 𝐼2) =
∑ (𝐼1(𝑥) − 𝐼2(𝑥))𝑥𝜖𝛺
√∑ 𝐼1(𝑥)2 ∗ ∑ 𝐼2(𝑥)2𝑥𝜖𝛺𝑥𝜖𝛺
 (2-7) 
 
 
Mutual Information  
Mutual information (MI) is a useful method for when each image is of a different modality: 
 
 𝑀𝐼(𝐼1, 𝐼2) = 𝐻(𝐼1) + 𝐻(𝐼2) − 𝐻(𝐼1, 𝐼2) (2-8) 
 
where 𝐻(𝐼1) and 𝐻(𝐼2) (Eq. 2-9) represent the marginal entropies and 𝐻(𝐼1, 𝐼2) (Eq. 2-10) 
represents joint entropy.  
 
 𝐻(𝐼) = −∑𝑝(𝑖) log 𝑝(𝑖)
𝑖
 (2-9) 
 
where i spans all intensities in I.  
 
 𝐻(𝐼1, 𝐼2) = −∑𝑝(𝐢) log 𝑝(𝐢)
𝐢
 (2-10) 
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Where i spans all intensity pairs between I1 and I2. The probabilities are estimated from the 
images.  
 
Another technique is geometry-based DIR, which does not directly use voxel intensities but uses 
features extracted from the images such as landmarks or anatomical surfaces. Some approaches 
have been proposed to combine intensity-based and geometry-based DIR. One such approach 
used in this Ph.D. and implemented in the treatment planning system RayStation is the 
ANAtomically CONstrained Deformation Algorithm (ANACONDA) [96]. This hybrid approach 
combines intensity information as well as contours defined manually on anatomical surfaces. For 
the ANACONDA method, a smooth DVF is optimized using the quasi-Newton algorithm.  
Similarity between the images is determined by correlation coefficients, which guide the DVF. 
Regularization of the DVF is done by the weighted Dirichlet energy, which measures variability 
of the function. Regularization with this method involves first resolving the DVF smoothness 
and invertibility, and then penalizing large deviations in the regions of interest (ROI). 
Controlling ROIs can be chosen by the user to guide the DIR, which in addition to the intensity-
based part, makes it a hybrid algorithm. Deformation of each ROI surface is computed by 
registering distance maps representing the surface.  
 
2.2.2 Biomechanical Model-Based DIR Algorithms 
 
Biomechanical model-based DIR uses material properties of the tissue in the image to deform the 
image. These material properties define the stiffness and flexibility of the tissue. The 
biomechanical model-based DIR discussed in this dissertation is based on finite element models 
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(FEM) of the structures depicted in the images. In a FEM-based DIR algorithm, each ROI is 
represented by a series of joined nodes that create tetrahedrons to approximate the surface. FEM 
analysis solves the geometric relationship between tetrahedrons. For biomechanical model-based 
DIR, boundary conditions define motion and deformation of the tissue.     
 
 
FEM-based DIR algorithms are particularly useful compared to intensity-based algorithms for 
multi-modality applications and in cases where anatomical deformation is complex.  FEM-based 
DIR algorithms allow for the implementation of dose-based boundary conditions to describe the 
volumetric response of tissue and have been validated for several organ sites. Polan et al [97] 
applied dose-driven volumetric response to an FEM-based DIR algorithm to improve the 
accuracy of modeling anatomical changes in the liver. Velec et al [98] demonstrated that the 
accuracy of FEM-based DIR was near image voxel resolution accuracy for multiple image 
modalities for the thorax, abdomen, and prostate. Another advantage of using FEM-based DIR 
algorithms is the ability to apply internal boundary conditions to organs. Cazoulat et al [99] 
added boundary conditions to lung vasculature and significantly improved the accuracy in 
modeling lung and tumor response during radiation therapy. Yan et al [100] developed a 
biomechanical model of an elastic body in order to quantify the organ motion of radiation 
therapy patients.   
 
The biomechanical model-based DIR algorithm used for the studies described in this thesis was 
Morfeus [63], which is based on organ segmentations. With Morfeus, we can create a dense DVF 
between the reference image and target image. Based on contours, triangular surfaces meshes are 
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generated to represent the organs of interest. Material properties (Young’s Modulus and 
Poisson’s Ratio) are assigned to the organs of interest. Soft tissues are modeled as linear-elastic 
materials, which restore to their initial state after the load is removed. We characterize the 
material using the elastic modulus (E), which is the slope of the plot of stress over strain, and 
Poisson’s ratio (𝜈), which is the ratio of the transverse strain to the axial strain. The shear 
modulus, G, is defined by shear stress divided by angular deformation. The bulk modulus, K, is 
defined by the load divided by the volumetric change. The aforementioned variables are related 
in the following equations. 
 
 𝐺 =  
𝐸
2(1 + 𝜈)
 (2-11) 
 
 𝐾 =  
𝐸
3(1 − 2𝜈)
 (2-12) 
 
Hooke’s law represents the relationship linking stress and strain for elastic models, and is 
defined in the equation 
 𝜎 = 𝐶𝜀 (2-13) 
 
where the stress and strain are represented by σ and 𝜀, and the elastic moduli is represented by C.  
 
A tetrahedral FEM model of all organs is generated. For each structure, a surface projection 
algorithm determines the displacement of the surface nodes. Those displacements are used as 
boundary conditions in the model. Two different surface projection algorithms have been 
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previously implemented in Morfeus, in order to determine boundary conditions. The first method 
is HYPERMORPH, which is an algorithm in HYPERMESH, which is a FEM pre-processor 
from Altair Engineering in Troy, MI. HYPERMORPH relies on the FEM surface meshes 
generated based on the organs. The secondary mesh is converted to a surface. Next, an initial 
center-of-gravity (COG) registration is completed between the two meshes. The surface 
tetrahedrals are grouped into domains that depend on the FEM’s curvature. The nodes are then 
guided in each domain by a “handle”. The base model domains are mapped to the secondary 
model domains, and the deformable alignment is guided by the handle and then an orthogonal 
node projection. This alignment is performed from node to surface. Finally, boundary conditions 
are based on the vector difference of each mode, before and after alignment. Another surface 
projection algorithm has been recently added to handle organs presenting large deformations. 
This algorithm is based on the accelerated Demons algorithm. The Demons algorithm [94] is a 
greyscale image-, or intensity-based method. Because of the similar intensities between images, 
this method is used for registration between CT images in RT. The forces of the Demons method 
can be described using the optical flow equation. The following equation describes the 
displacement ?⃗⃗? of a point from the reference image, R, to the point corresponding from the target 
image, T:   
 
 ?⃗⃗? =
(𝑡 − 𝑟)∇⃗⃗𝑟
|∇⃗⃗𝑟|
2
+ (𝑡 − 𝑟)2
 (2-14) 
 
where ?⃗⃗? represents the displacement in each direction, t and r represent the intensities of the 
target and references images, and ∇⃗⃗𝑟 represents the reference image gradient. Iteratively, the 
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Demons algorithm solves the equation (Eq. 2-15) for each voxel and composes the displacement 
field ?⃗⃗? with the global displacement field ?⃗⃗?: 
 
 ?⃗⃗?𝑛 = ?⃗⃗?𝑛 + ?⃗⃗?𝑛−1 (2-15) 
 
 
In order to minimize noise and ensure smoothness of the tranformation the global DVF is filtered 
with a Gaussian kernel. Since the deformation is driven only by the gradient of the reference 
image, the method was improved in [101] with the addition of an active force to the deformed 
(target) image. This active force, 𝑓𝑡⃗⃗⃗ ⃗, can be described in the following equation. 
 
 𝑓𝑡⃗⃗⃗ ⃗ =  − 
(𝑟 − 𝑡)∇⃗⃗𝑡
|∇⃗⃗𝑡|
2
+ (𝑟 − 𝑡)2
 (2-16) 
 
Finally, the total force of a point can be described with the equation 
 
 𝑓 = 𝑓𝑟⃗⃗⃗ ⃗ + 𝑓𝑡⃗⃗⃗ ⃗ = (𝑡 − 𝑟) ∗ (
∇⃗⃗𝑟
|∇⃗⃗𝑟|
2
+ (𝑟 − 𝑡)2
+
∇⃗⃗𝑡
|∇⃗⃗𝑡|
2
+ (𝑟 − 𝑡)2
) (2-17) 
 
where 𝑓𝑟⃗⃗⃗ ⃗ represents the force from the gradient of the reference image and 𝑓𝑡⃗⃗⃗ ⃗ represents the force 
from the gradient of the target image. These force calculations are appropriate with relatively 
small deformations. However, there are often large deformations in clinical cases, so 
multiresolution method [102] was applied. This method applies an iterative demons diffusion 
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approach, based on low-resolution images, and increases calculation speed by improving the 
convergence. An additional normalization factor (a) was also applied. With this incorporation of 
a, adjustments to the force strength at each iteration is possible. This factor is applied as shown 
in the following equation 
 
 𝑑 = (𝑡 − 𝑟) ∗ (
∇⃗⃗𝑟
|∇⃗⃗𝑟|
2
+ 𝑎2(𝑟 − 𝑡)2
+
∇⃗⃗𝑡
|∇⃗⃗𝑡|
2
+ 𝑎2(𝑟 − 𝑡)2
) (2-18) 
 
where larger deformations require smaller a values.  
 
Morfeus was used in this work to align the parotid glands after both positional changes and dose 
response. Using Morfeus to describe the changes during radiation therapy is important because 
FEM-based deformable image registration algorithms can be used to show not just the changes in 
the surface of the organs, but also to model what is happening internally. The Morfeus process is 
outlined in Fig. 2-13.  
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Figure 2-11. Depiction of Morfeus process.  
Using a pre-treatment (initial) and a post-treatment (secondary) image, Morfeus aligns the initial image to the 
corresponding secondary image. A volumetric mesh is generated and material properties are assigned to the initial 
image. Then, a surface mesh is generated from the secondary image. The surface correlation is calculated and 
applied as boundary conditions to the initial model. Finally, the finite element analysis (FEA) solves the deformation 
between the initial image and the secondary image.  
 
2.2.3 Dose Accumulation  
 
Upon completion of any fraction during radiation therapy, the dose (d) can be accurately 
accumulated using DIR. A CBCT from a daily treatment fraction is deformed to the planning 
CT. The DVF (U) is then used to deform the dose from the CBCT onto the planning CT, which 
allows the comparison between the planning dose and delivered dose. Ultimately, accumulating 
the dose using DIR can indicate the need for re-planning the patient. After completion of 
treatment, assessment of the treatment efficacy is performed based on the acquisition of follow-
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up images. These images need to be registered to the image on which the accumulated dose has 
been calculated (Fig. 1.11) to better understand the correlation between delivered dose and 
outcome. The ultimate goal is to optimize treatment strategies for future patients. The following 
equation describes the daily accumulated dose:  
 
 𝑑(𝑥) = 𝐷(𝑥 + 𝑈(𝑥)) (2-19) 
 
where d is the daily accumulated dose at the voxel coordinate x, and D is the deformed daily 
dose distribution based on the DVF U. This daily accumulated dose is calculated for each 
fraction and all doses are summed to calculate the total accumulated dose.  
 
 
Figure 2-12. Follow-up CT scan with accumulated dose overlaid. 
 
 Adaptive Radiation Therapy  
 
As patients progress through radiation therapy, the tumor and normal tissue may change due to 
weight loss and tumor response. As tissues change during radiation therapy, the radiation 
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treatment plan may no longer correspond to the patient anatomy. Continuing to use the original 
treatment plan may lead to an unacceptable dose deviation. In this case, creating a new treatment 
plan that is optimal for the new patient geometry is necessary. This process, ‘adaptive 
radiotherapy’, is the process where a new radiation treatment plan is triggered based on new 
information acquired during the radiation therapy course. For this, a new CT scan is usually 
acquired on which the contours are delineated to optimize a new treatment plan, based on the 
new anatomy of the patient.    
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Chapter 3. A Simulation Study to Assess the Potential Impact of Developing 
Normal Tissue Complication Probability Models with Accumulated Dose 
 
Current practice in radiation oncology involves the use of historic population models for 
predicting toxicity. These models are based on the planned dose to a specific organ. Recent 
studies explored the deviations between planned and delivered dose to the liver [62,64].  
 
 
When NTCP models were first developed, accurate dose accumulation to estimate the true 
delivered dose to the organ over treatment was not possible. However, accurate dose 
accumulation is now possible, and the same classic, planned dose-based models are still being 
used in the clinic. The radiation dose to liver tumors is often limited by the surrounding normal 
tissue. As the normal tissue in the abdominal region consists mainly of serial structures, which 
lose function completely when any part of the organ loses function, the priority of radiation 
treatment for liver cancer is to spare the gastro-intestinal organs. Limiting the dose to normal 
tissue can potentially limit the dose to the tumor and therefore tumor control. As there are 
potential deviations between the planned and delivered dose, the planned dose-based model is 
not necessarily accurate, and with the possibility of dose accumulation in clinical trials, it is now 
possible to generate more accurate toxicity models. This chapter explores the potential clinical 
impact of generating new toxicity models based on the accumulated dose to the patient.  
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 Abstract 
 
The purpose of this study is to analyze the potential clinical impact of differences between 
planned and accumulated dose on the development and use of normal tissue complication 
probability (NTCP) models. Thirty patients previously treated with SBRT for liver cancer and 
for whom accumulated dose was computed, were assessed retrospectively. The linear quadratic 
equivalent dose at 2Gy per fraction (LQED2) and generalized equivalent uniform dose (gEUD) 
were calculated for planned and accumulated dose. Stomach and duodenal Lyman-Kutcher-
Burman (LKB) NTCP models (α/β=2.5, n=0.09) were developed based on planned and 
accumulated gEUD and the differences between the models assessed. In addition, the error in 
determining the probability of toxicity based on the planned dose was evaluated by comparing 
planned doses into the NTCP model created from accumulated dose. The standard, planned-dose 
NTCP model overestimates toxicity risk for both the duodenal and stomach models at doses 
below approximately 20Gy (6-fractions), and underestimates toxicity risk for doses above 
approximately 20Gy (6-fractions). Building NTCP models using accumulated dose rather than 
planned dose changes the predicted risk by up to 16 % (Mean=6%,SD=7%) for duodenal toxicity 
and 6% (Mean=2%,SD=2%) for stomach toxicity. For a protocol planning a 10% iso-toxicity 
risk to the duodenum, a 15.7Gy (6-fractions) max dose constraint would be necessary when 
using standard NTCP models based on planned dose, while a 17.6Gy (6-fractions) max dose 
would be allowed when using NTCP models based on accumulated dose. Assuming that 
accumulated dose is a more accurate representation of the true delivered dose than the planned 
dose, this simulation study indicates the need for prospective clinical trials to evaluate the impact 
of building NTCP models based on accumulated dose.  
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 Introduction  
 
Stereotactic body radiation therapy (SBRT) delivers high precision external beam radiation 
therapy (EBRT) treatment in 2-5 fractions. The goal of using SBRT is to deliver an ablative dose 
to the tumor while sparing normal tissue leading to lower toxicity [103]. While SBRT has been 
demonstrated to increase local control of liver cancer [104], toxicity risks must still be 
acknowledged for liver and luminal gastrointestinal (GI) structures [105]. Dose escalation has 
the potential to improve local control [106]. However, increase in dose is often limited by normal 
tissue toxicity risk. Based on previous studies [25], approximately 30% of patients are dose 
limited based on GI toxicity. Overestimating toxicity risk can lead to conservative treatment for 
the patient, potentially leading to lower chances of tumor control.  Underestimating toxicity risk 
can subject the patient to unplanned risks. It is therefore critical to have an accurate 
understanding of toxicity to normal tissue. Significant efforts have been made in the 
development and validation of accurate Normal Tissue Complication Probability (NTCP) models 
[107-110], which aim to characterize the correlation between dose and the likelihood of side 
effects [111]. Specifically, Lyman-Kutcher-Burman (LKB) NTCP models have been used to 
investigate the dose-volume response for liver cancer [112].  
 
LKB NTCP models have been previously developed for duodenal toxicity [108] demonstrating 
that the model can predict outcomes after SBRT. In addition, a separate investigation showed 
that the Lyman NTCP model can predict gastric bleeding [107], demonstrating that patients with 
cirrhosis are at increased risk. Both studies built the NTCP models based on the planned dose to 
each patient. Recent retrospective studies have shown that the planned dose differs from the 
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accumulated dose [25,113,114], especially when evaluating the maximum dose to luminal GI 
structures, such as the duodenum and stomach, for which the differences could reach 42% and 
14%, respectively, of the prescribed dose [25]. It is hypothesized that building NTCP models 
based on accumulated dose will lead to a substantially different model, which may have clinical 
impact. The goal of this work is to evaluate how the known uncertainty between planned and 
delivered dose limits translates into potential uncertainties in NTCP modeling, and to determine 
the differences in the model if accumulated dose was used in the derivation of the model 
parameters.  
 
Previous work supports the hypothesis that accumulated dose can improve understanding of 
clinical outcomes of SBRT, demonstrating the accumulated dose to the GTV more strongly 
predicts for total time to local progression [114]. The current study builds on this work, assessing 
the impact of accumulated dose on NTCP models by comparing LKB NTCP models based on 
planned dose with those based on accumulated dose. Preceding clinical trials, the aim of this 
study is to assess the potential differences in the development of the NTCP models using 
accumulated dose versus planned dose. The second aim is to apply these models for patient 
specific assessment.  
 
 Methods and Materials 
 
3.3.1 Patient Data 
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A previous study retrospectively evaluated the deviations between planned and accumulated 
dose to tumors and normal tissues in liver SBRT in 30 patients [25]. The patients were treated on 
an institutional review board-approved trial under free-breathing conditions, with 6 fractions to 
an individualized risk-based dose of 27-30Gy. Daily cone-beam CT (CBCT) guidance was 
performed. For each patient, the dose was accumulated by registering the daily inhale/exhale 
CBCT to the planning CT scan with Morfeus, an in-house biomechanical model-based 
deformable registration algorithm (DIR) [63]. For each of the thirty patients, planning dose and 
accumulated dose for stomach and duodenum were used in the Lyman NTCP model.  
Dose Accumulation 
 
The dose accumulation was previously reported [25] and will be briefly described here for 
completeness. Morfeus was used to accumulate the dose for each patient. The dose distribution 
from the static radiation treatment plan was calculated in the treatment planning system on the 
exhale planning CT and the inhale planning CT. Both dose distribution files were imported into 
Morfeus. In Morfeus, the organs are described using finite element models, which represents 
substructure within the organs through tetrahedral elements. Through the DIR, the locations of 
the tetrahedral elements can be tracked between the exhale and inhale images of 4D scans. 
Interpolation of dose matrices onto the position of each element at exhale, inhale, and four 
intermediate phases is performed to accumulate the dose. The weighting of each phase was 
determined by the time spent at that phase and the elemental position in the breathing cycle. 
Finally, a summation of elemental dose over the breathing cycle was calculated to determine the 
accumulated dose.       
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The planned dose is defined as the static clinical planned dose, which was found by interpolating 
the dose matrix from the exhale CT onto the initial tetrahedral mesh constructed from the 
anatomy on the exhale CT. The calculation of this dose does not include any changes due to 
breathing motion or setup error.  
 
Accumulated dose refers to the dose accumulated over SBRT accounting for residual setup 
errors (e.g. those errors still present following daily image guidance), respiratory motion, shifting 
of the liver, and deformation. To account for setup errors and organ deformation present at each 
fraction, the exhale CT is deformed to the exhale CBCT of each fraction. Next, to account for 
daily breathing motion, the exhale CT is deformed from the exhale CBCT to the inhale CBCT of 
each fraction.  To accumulate the dose, dose matrices from the exhale CT and inhale CT are 
interpolated onto the deformation map from the exhale to inhale CBCT of each fraction. Finally, 
the doses from the 6 fractions of treatment are summed. In order to accumulate the dose, DIR 
tracked anatomical motion and deformation in the dose matrices of the initial planning 4D CT.  
 
3.3.2 Differences between planned and accumulated doses 
 
Percent change (PC) from planned to accumulated mean dose was analyzed for duodenum 
(N=30), stomach for primary liver cancer (non-cirrhotic) patients (N=15), and stomach for 
cirrhotic patients (N=15), calculated by the equation 
 
 𝑃𝐶𝑑𝑜𝑠𝑒 =
𝐴𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑒𝑑 𝐷𝑜𝑠𝑒 − 𝑃𝑙𝑎𝑛𝑛𝑒𝑑 𝐷𝑜𝑠𝑒
𝑃𝑙𝑎𝑛𝑛𝑒𝑑 𝐷𝑜𝑠𝑒
∗ 100  (3-1) 
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3.3.3 NTCP Models – Change in probability of toxicity 
 
The delivered and accumulated doses (in the form of tabular DVH) were biologically corrected 
to the Linear Quadratic Equivalent Dose at 2Gy per fraction (LQED2), using an α/β ratio of 2.5 
[107]. The gEUD was calculated with n=0.09. The Lyman NTCP model, shown in equation 3-2, 
was used for toxicity modeling in this study.  
 
 𝑁𝑇𝐶𝑃 = Ф(
𝑔𝐸𝑈𝐷 − 𝑇𝐷50
𝑚 · 𝑇𝐷50
)  (3-2) 
 
The function Φ represents the NTCP model [115] where gEUD is evaluated using equation 
[105], TD50=24.6 and m=0.23 for duodenum [108], TD50=22 and m=0.21 for stomach and 
cirrhosis [107], and TD50=56 and m=0.21 for stomach and no cirrhosis [107].  
 
The percent change (PC) in NTCP from planned to accumulated dose was calculated using the 
equation  
 𝑃𝐶𝑁𝑇𝐶𝑃 = 
𝑁𝑇𝐶𝑃 𝐴𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑒𝑑 − 𝑁𝑇𝐶𝑃 𝑃𝑙𝑎𝑛𝑛𝑒𝑑
𝑁𝑇𝐶𝑃 𝑃𝑙𝑎𝑛𝑛𝑒𝑑
∗ 100   (3-3) 
 
 
  
3.3.4 Simulated Toxicities for Duodenum and Stomach 
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Toxicity models were simulated for duodenum and stomach with cirrhosis. Stomach without 
cirrhosis was not modeled, as there were no patients with an absolute change in NTCP of greater 
than 5% between the accumulated and planned dose.  In order to simulate toxicity models for a 
larger cohort of patients than was used in the study, a resampling process was developed. 
            
Figure 1 depicts the planned dose over the accumulated dose for the original 30 patients for 
duodenum, and the 15 cirrhosis patients for stomach. Based on the trends seen in Figure 1, a 
model was fit to predict planned dose given accumulated dose in order to resample data points. 
 
 𝑑𝑝𝑙𝑎𝑛~𝑁(𝑑𝑎𝑐𝑐 + 𝛽𝑑𝑎𝑐𝑐 , 𝜎
2𝑑𝑎𝑐𝑐)   (3-4) 
 
Where dplan is planned dose, dacc is the accumulated dose, and β (bias function of dose) and σ2 are 
parameters estimated by the linear regression model shown in Figure 1. These parameters were 
estimated via maximum likelihood.  
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Figure 3-1. Planned Vs. Accumulated Dose Plots.  
Planned Vs Accumulated Dose for Duodenum (a) and Stomach with Cirrhosis (b). The solid green line depicts the 
mean, the dashed line shows the 95% confidence limits for regression, and the solid gray line represents the case that 
planned dose and accumulated dose are equal.    
 
NTCP models are typically estimated using planned dose values. To quantify the effect of 
differences between planned and accumulated doses on model parameter estimation, the 
following steps were performed: 
1. The distribution of planned dose was estimated as a function of accumulated dose, 
which involved both estimation of systematic bias (i.e. β≠1 in Eq. 6) and random 
variation of planned dose about accumulated dose. In the case that the two dose terms 
agreed perfectly, there would be neither bias (i.e. β=1) nor variation (i.e. σ=0). 
2. Both toxicity values were simulated (using the accumulated dose NTCP model) and 
planned dose values (using Eq. 6) from the observed delivered dose values in the 
study (n=30). Larger sample sizes can overcome variation between planned and 
accumulated dose. However, larger sample sizes do not overcome systematic bias. 
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Thus, studies of size 30, 150, or 600 patients were simulated by using each observed 
patients delivered dose value 1, 5, or 20 times. Because a random toxicity outcome 
and random planned dose value was simulated using the relationship established in 
Eq. 6, the multiple outcomes simulated from a single patient in the 30 patient dataset 
were distinct.  
3. For each of the simulated studies, the NTCP model parameters were estimated based 
on the planned dose values.  
4. Steps 2 and 3 were repeated 2,000 times. Finally, the mean NTCP curve was plotted 
as well as the 10th and 90th percentiles of the curves.  
 
3.3.5 NTCP Models – Change in probability of toxicity  
 
Finally, the deviations in the probabilities of toxicity between the standard and accumulated 
NTCP models were quantified. As the true probability of toxicity risk is unknown, this was 
estimated with the probability of toxicity risk of the dacc derived from the accumulated dose 
model (NTCP1). The dplan and dacc (in maximum dose to 0.5cc) of each patient in the study were 
correlated to the probability of toxicity risk using each NTCP model. NTCP2 was defined as the 
probability of toxicity risk of dplan derived from the standard model and NTCP3 was defined as 
the probability of toxicity risk of dplan derived from the accumulated model. The error in the 
standard model was calculated as the difference between NTCP2 and NTCP1. The error in the 
accumulated model was calculated as the difference between NTCP3 and NTCP1. 
 
 Results 
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The previously reported deviations of 5% or greater in 70% of the patients [25] translates to a 
deviation of greater than 5% NTCP for 57% of the patients for duodenum and 60% of patients 
for stomach with cirrhosis in the current study.  
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Figure 3-2. Percent Change in Dose and NTCP.  
Percent Change from Planned to Accumulated Dose (PCdose) by Planned Dose (Gy) for Stomach and Duodenum and 
Percent Change in NTCP by Percent Change in Dose (PCNTCP) for Stomach and Duodenum. The solid gray line 
represents a zero percent change in dose. 
 
3.4.1 NTCP Models for Duodenum and Stomach 
 
 63 
For duodenal toxicity, the difference between NTCP based on accumulated dose and NTCP 
based on planned dose is substantial (Figure 3). Table 1 shows the results from deriving error 
from the toxicity models for duodenum for the 30 patients with dose accumulation. It was 
assumed that the toxicity risk using the accumulated dose value and the probability of toxicity 
risk derived from the accumulated model was the most accurate assessment of the toxicity risk. 
The error in using the planned dose with the standard model was 6% (SD=7%), where the error 
in using the planned dose with the accumulated model was 4% (SD=7%).  
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Figure 3-3. Probability of Duodenal and Gastric (with Cirrhosis) Toxicity.  
Probability for simulations of 30, 150, and 600 patients. The black line represents the Lyman NTCP by dose. The 
solid red line represents the mean NTCP based on simulations with accumulated dose (dacc). The green lines 
represent the mean NTCP based on simulations with planned dose (dplan).The dashed lines represent the 10th and 90th 
percentiles.   
 
Table 3-1. Duodenal NTCP results.  
*Assumption that this model is closest to the true risk based on the most accurate measurement of delivered dose.  
 
Patient 
Doseplanned 
max dose 
to 0.5cc 
[Gy] 
NTCP2 
Doseplanned, 
Modelstd 
[%] 
NTCP3 
Doseplanned, 
Modelacc 
[%] 
Doseacc 
max dose 
to 0.5cc 
[Gy] 
NTCP1* 
Doseacc, 
Modelacc 
[%] 
|
𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞
𝐍𝐓𝐂𝐏𝟐 −
𝐍𝐓𝐂𝐏𝟏
| 
 
|
𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞
𝐍𝐓𝐂𝐏𝟑 −
𝐍𝐓𝐂𝐏𝟏
| 
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1 29.91 66.61 82.93 29.41 80.55 13.94 2.38 
2 25.44 45.72 55.86 20.91 25.18 20.54 30.68 
3 8.63 1.74 0.28 6.67 0.10 1.63 0.18 
4 6.67 0.96 0.10 5.86 0.07 0.90 0.04 
5 15.32 9.34 4.91 15.12 4.58 4.76 0.33 
7 29.70 65.66 81.94 29.74 82.14 16.48 0.19 
8 0.79 0.13 0.00 0.77 0.00 0.12 0.00 
9 10.42 2.87 0.66 9.04 0.34 2.53 0.32 
11 0.69 0.12 0.00 0.64 0.00 0.12 0.00 
12 9.77 2.40 0.49 9.69 0.47 1.93 0.02 
13 8.70 1.77 0.29 5.65 0.06 1.71 0.23 
14 0.64 0.12 0.00 0.63 0.00 0.12 0.00 
15 1.94 0.19 0.01 1.59 0.01 0.19 0.00 
16 9.61 2.29 0.45 9.29 0.39 1.90 0.06 
17 19.07 19.16 15.94 12.36 1.55 17.61 14.39 
18 32.28 76.18 91.47 27.76 71.44 4.74 20.03 
19 31.22 72.08 88.16 30.92 87.08 15.00 1.08 
20 32.35 76.42 91.64 30.06 83.59 7.17 8.06 
21 29.59 65.20 81.45 29.52 81.07 15.88 0.37 
22 30.08 67.35 83.70 28.75 77.15 9.81 6.55 
23 1.32 0.16 0.00 1.26 0.00 0.15 0.00 
24 6.56 0.93 0.10 5.79 0.06 0.87 0.03 
25 1.47 0.16 0.00 1.30 0.00 0.16 0.00 
26 22.39 31.78 34.34 20.75 24.26 7.51 10.07 
27 23.26 35.59 40.27 21.12 26.39 9.20 13.88 
28 24.19 39.80 46.83 22.88 37.62 2.18 9.21 
29 33.22 79.52 93.76 33.82 94.94 15.43 1.18 
30 31.25 72.20 88.26 30.20 84.19 12.00 4.07 
31 10.15 2.66 0.58 7.00 0.12 2.54 0.46 
32 9.57 2.27 0.44 8.49 0.26 2.01 0.18 
     Average 6.30 4.13 
     SD 6.53 7.31 
 
 
 
For stomach toxicity, the difference between NTCP based on accumulated dose and NTCP based 
on planned dose is less substantial (Figure 3). Table 2 shows the results from deriving error from 
the toxicity models for stomach for the 30 patients with dose accumulation. The error in using 
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the planned dose with the standard model was 3% (SD=3%), where the error in using the 
planned dose with the accumulated model was 3% (SD=4 %).  
 
 
Table 3-2. Stomach NTCP results:  
*Assumption that this model is closest to the true risk based on the most accurate measurement of delivered dose.  
 
Patient 
Doseplanned 
max dose 
to 0.5cc 
[Gy] 
NTCP2 
Doseplanned, 
Modelstd 
[%] 
NTCP3 
Doseplanned, 
Modelacc 
[%] 
Doseacc 
max dose 
to 0.5cc 
[Gy] 
NTCP1* 
Doseacc, 
Modelacc 
[%] 
|
𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞
𝐍𝐓𝐂𝐏𝟐 −
𝐍𝐓𝐂𝐏𝟏
| 
 
|
𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞
𝐍𝐓𝐂𝐏𝟑 −
𝐍𝐓𝐂𝐏𝟏
| 
 
1 29.21 90.23 94.19 29.24 94.26 4.03 0.08 
2 7.10 0.19 0.09 9.08 0.31 0.11 0.22 
3 10.31 1.06 0.64 10.09 0.56 0.51 0.08 
4 17.63 17.65 16.85 17.88 18.28 0.63 1.43 
5 2.86 0.01 0.00 3.22 0.01 0.01 0.00 
7 20.57 35.83 37.46 19.51 29.06 6.77 8.40 
8 13.94 5.17 4.05 12.36 1.91 3.26 2.15 
9 19.89 31.05 31.97 19.67 30.24 0.81 1.73 
11 0.61 0.00 0.00 0.61 0.00 0.00 0.00 
12 12.31 2.66 1.86 11.96 1.55 1.11 0.31 
13 23.55 58.30 63.03 22.20 51.50 6.80 11.53 
14 23.05 54.58 58.89 22.91 57.63 3.05 1.27 
15 26.44 77.80 83.33 23.63 63.77 14.03 19.56 
16 19.46 28.22 28.72 19.96 32.47 4.25 3.75 
17 28.18 86.43 91.14 27.78 89.65 3.22 1.48 
18 28.59 88.03 92.45 26.32 82.73 5.30 9.72 
19 5.62 0.08 0.03 5.56 0.03 0.05 0.00 
20 31.28 95.40 97.79 29.89 95.68 0.28 2.10 
21 31.07 95.02 97.56 31.65 98.20 3.17 0.64 
22 32.56 97.30 98.88 31.98 98.47 1.17 0.42 
23 29.23 90.30 94.24 30.09 96.09 5.79 1.85 
24 31.74 96.18 98.25 31.15 97.65 1.48 0.60 
25 18.63 23.06 22.86 17.96 18.72 4.34 4.14 
26 27.12 81.49 86.79 26.54 83.89 2.40 2.90 
27 16.79 13.84 12.74 15.43 7.66 6.17 5.07 
28 22.86 53.06 57.19 22.80 56.70 3.64 0.49 
29 11.14 1.58 1.01 12.15 1.72 0.14 0.71 
30 30.28 93.27 96.40 28.59 92.45 0.83 3.95 
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31 17.66 17.82 17.04 16.96 13.49 4.33 3.54 
32 17.12 15.28 14.28 15.68 8.45 6.83 5.83 
     Average 3.15 3.13 
     SD 3.08 4.30 
 
 
In an iso-toxicity protocol with a 10% risk to the duodenum, 17.6Gy (6-fractions) would be 
allowed if the accumulated model was applied, while 15.7Gy (6-fractions) would be allowed if 
the standard model was applied. While the stomach model shows only slight differences between 
the standard and accumulated NTCP models at this probability of toxicity risk, the standard 
model still overestimates toxicity risk. With a 10% limit on toxicity risk to the stomach, the 
accumulated model would allow 16.1Gy (6-fractions), while the standard model would allow 
15.8Gy (6-fractions).  
 
The bias in the planned doses in Figure 3 is reflected in the differences between the solid red and 
green lines. Increasing sample size does not diminish this difference. The dashed green lines 
indicate variation in the fitted NTCP curves between trials. As the sample size increases from 30 
to 600, the variation between hypothetical trials becomes very small so that almost any 600 
patient study will result in nearly the same biased NTCP curve (solid green line).  
 
The greatest deviation between the probability of toxicity risk based on the accumulated model 
and the probability of toxicity based on the planned model occurs at a planned dose of 
approximately 30Gy (6-fractions) for duodenum (Figure 4a) and 25Gy (6-fractions) for stomach 
(Figure 4b). This deviation is greater for duodenum (16% greater probability of toxicity risk 
based on the accumulated model) than for stomach (6% greater probability of toxicity risk based 
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on the accumulated model). For both the duodenum and stomach models, the planned model 
overestimates the probability of toxicity risk for planned doses until the crossover point of 21Gy 
(6-fractions) for duodenum and 18Gy (6-fractions) for stomach, and overestimates the 
probability of toxicity after the crossover point. 
 
 
Figure 3-4. Probability of Duodenal Toxicity [%] (Based on Accumulated Model) for Duodenum and Stomach.  
The blue line represents the probability of toxicity derived from the accumulated dose NTCP model versus planned 
dose. The orange line represents the difference between probability of toxicity using the accumulated model and the 
planned model. The largest difference for duodenum occurs at planned dose of approximately 30Gy (toxicity risk of 
approximately 80%). The largest difference for stomach occurs at planned dose of approximately 26Gy, (toxicity 
risk of approximately 80%. 
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 Discussion  
 
The potential impact of the deviation between the planned and delivered dose on the 
development of NTCP models was investigated for liver SBRT patients. Deviations were 
observed between the NTCP curves based on accumulated dose and standard NTCP curves for 
duodenal toxicity, indicating the potential impact that updated NTCP curves could have on 
patient treatment. For gastric toxicity, only modest deviations were observed, with a maximum 
deviation of 14%. However, more substantial and potentially clinically significant deviations 
were seen for the duodenum, with an average deviation of 6% and a maximum deviation of 21%. 
For both duodenal toxicity and gastric toxicity, standard NTCP curves overestimated toxicity 
risk at lower doses (for doses up to 21.5Gy based on 6-fraction dose for duodenum and up to 
19Gy based on 6-fraction dose for stomach). Deriving probability of toxicity risk for planned 
dose using simulations of NTCP curves based on accumulated dose yields a smaller error than 
deriving probability of toxicity risk for planned dose using the standard, planned dose NTCP 
model.  
 
This study was based on 30 original patients that were resampled to simulate a cohort of 150 and 
600 patients to build statistical Lyman NTCP models. Due to the limited number of patients in 
the original analysis [25], true models could vary from the simulations. In addition, these 30 
patients were treated at one institution, indicating the possibility of dependence of the results to 
the treatment setup and treatment planning tendencies. As with all models, there is some 
uncertainty and this NTCP model has been shown to potentially overestimate the toxicity risk 
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[116]. However, the focus of this paper is to investigate the potential difference between NTCP 
models given the known differences between accumulated and planned dose, to determine if 
there is a strong need to gather multi-institutional data to ensure the accuracy of these models. 
The results of this simulation study requires confirmation through prospective studies. Further 
affirmations are necessary for the impact assessment on normal tissue complications of the 
stomach and duodenum. In an image guided radiation therapy (IGRT) protocol, the goals are 
normally targeting tumor alignment and avoiding normal tissue. A complicated relationship 
exists between the planned and accumulated dose due to dose distribution and high dose regions, 
and a study with many more than 30 patients is necessary to understand this relationship. 
 
The 30 patients in the current study were originally selected for a secondary analysis of SBRT 
dose accumulation [25], from the patients treated on phase I/II clinical trials [106,117,118] based 
on having available CBCT imaging and breathing motion > 5mm. They were not 
specifically selected based on any clinical outcome including toxicity. There were no grade 3 or 
higher GI toxicities in this limited sample of 30 patients. There were 2 patients with Grade 3 
platelet counts, which are likely not related to duodenum or stomach toxicity, however are 
related to liver function and possibly non-classic radiation induced liver disease (RILD).  
 
Of the 30 patients included in this study, there were 9 patients with a dose-limiting normal tissue 
(i.e. PTV coverage or prescription dose was limited due to normal tissue toxicity risks) [64]. The 
toxicity models developed for this study showed that the planned-dose model overestimates 
toxicity risk in the average dose range, implying that the dose-limiting organs could potentially 
receive a higher dose with the same risk of toxicity. The 30 patients in this study did not have GI 
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toxicity, however this may have been the result of a conservative tumor dose. Understanding the 
dose-toxicity relationship is important especially in escalation studies because under-dosing due 
to misinterpreted normal tissue complication risk can be detrimental to local control, as the 
tumor will not receive as high a dose as possible. The QUANTEC report [116] on stomach 
toxicity acknowledged that there is limited data for GI toxicity, indicating a need for a better 
understanding of GI toxicity models, especially with the introduction of molecular agents in 
radiation therapy. The understanding of the dose being delivered is crucial so that the models 
used for radiation therapy are as accurate as possible and enable the highest therapeutic ratio 
possible.  
 
This study demonstrates the potential clinical importance of including accumulated dose in the 
development of NTCP models in future clinical trials. Since existing NTCP models are based on 
patient data that preceded volumetric daily imaging, they are based on only planned dose. 
Currently, equipment and software for volumetric daily imaging are available in the clinic, and 
therefore new DIR tools can be applied to perform dose accumulation. Future clinical trials 
should prospectively record delivered (accumulated) doses and toxicity outcomes in an effort to 
improve the understanding of the dose-response relationship. For example, in a phase III study 
[119] with 368 patients, more accurate toxicity data could be developed if accumulated dose was 
collected along with planned dose. This would require the collection of daily images or all 
patients to correlate true delivered dose with toxicity. This study supports the need for these trials 
to include the collection of imaging obtained at treatment delivery so that accumulated dose can 
be calculated. This simulation study suggests that deriving new NTCP models based on 
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accumulated dose will yield clinically significant results compared to the current models based 
on planned dose.  
 
In terms of trial design, one possibility is an observational design in which patients are treated 
per standard of care and both planned and accumulated dose values are recorded along with 
eventual toxicity outcome. How many patients are required will depend on many factors 
including the overall toxicity rate which is not always low. In primary liver cancer (HCC) 
patients treated with radiation, approximately 20% will experience toxicity defined as a change 
in Child-Pugh score of 2 points or more.  Demonstrating improved predictive performance of 
accumulated dose models would be one aim of a trial.  However, the primary aim would more 
likely be characterizing differences between planned and accumulated dose values including 
estimating how many patients had large deviations and seeking to identify in advance which 
patients were likely to have large dose deviations.  The size of the trial could be selected to 
achieve a desired level of precision in estimating the proportion of patients with large 
deviations.  As an example, if the true proportion of patients with large deviations were 0.10, a 
trial of 100 patients would result in a standard error of the estimated proportion equal to 0.03.  
 
Possible reasons for the numerical differences between the NTCP curves of the duodenum and 
stomach include variation of patients breathing magnitude and breathing trajectory. Regions of 
high dose gradient can differ based on the area of the organ and how it is affected by breathing 
motion. NTCP parameters, radiation treatment planning, and sensitivity of motion can all 
influence the final NTCP results for each organ, potentially causing the duodenum and stomach 
to have different numerical results. In addition, due to the limited number of patients, it may be 
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that potential deviations for the stomach were not observed, which may be observed in a larger 
population.   
 
This study focused on liver cancer and the organs at risk for toxicity during radiation treatment. 
However, the results may reflect the impact of incorporating accumulated dose in the 
development of luminal GI toxicity models in other abdominal treatment sites such as stomach, 
pancreas, or pelvic sites, where toxicity to GI structures are of clinical concern. Because 
accumulated dose is a more accurate prediction of delivered dose than planned dose, NTCP 
models for all sites, e.g. head and neck, could be improved if based on accumulated dose instead 
of planned dose. 
 
 Conclusion 
 
This work shows the importance of building new toxicity models based on accumulated dose. 
Accumulated dose provides an estimate of the radiation dose that the patient is actually 
delivered, rather than the dose that was planned before the start of their radiation treatment. 
Current toxicity models overestimate the toxicity risk to the duodenum and stomach at doses up 
to 21.5Gy and 19Gy, respectively, and underestimate the toxicity risk for higher doses. These 
findings indicate that the tumor could be delivered a higher dose, with the same probability of 
toxicity to the duodenum and stomach, which are both dose-limiting structures. Delivering a 
higher dose to the tumor potentially allows for higher tumor control, which could ultimately lead 
to a higher success rate for radiation treatment of liver cancer and lower rates of recurrence. This 
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work indicates the need for dose accumulation in clinical trials for liver cancer, as more accurate 
dose accumulation models could be developed based on this data. 
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Chapter 4. Predictive Models to Determine Clinically Relevant Deviations in 
Delivered Dose for Head and Neck Cancer 
 
Currently, the need to replan a HN cancer patient undergoing radiation therapy is based on the 
decision of the physician, based on factors such as weight loss. Rapid response from the tumor, 
weight loss, changes in the patient setup, and shrinkage of normal tissue can all occur during HN 
radiation therapy, causing drastically different anatomy than in the planning CT. In some cases, 
replanning is necessary, however, there does not yet exist a model to aide in the decision to 
replan a patient in radiation oncology. However, with the possibility of accumulating the dose to 
the patient, deviations between planned and accumulated dose can be calculated at every fraction 
during treatment, allowing for the possibility to develop such a model.  
 
 
This work aims to develop a model that can aid physicians in the decision to replan HN patients, 
with an explicit dose deviation threshold between planned and accumulated dose.  
 
 Abstract  
 
To improve the understanding of deviations between planned and accumulated dose and 
establish metrics to predict for clinically significant dosimetric deviations mid-way through 
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treatment to evaluate the potential need to replan during fractionated radiation therapy (RT). 100 
head and neck cancer patients were retrospectively evaluated. Contours were mapped from the 
planning CT to each fraction CBCT via deformable image registration (DIR). The dose was 
calculated on each CBCT and evaluated based on the mapped contours. The mean dose at each 
fraction was averaged to approximate the accumulated dose for structures with mean dose 
constraints and the daily max dose was summed to approximate the accumulated dose for 
structures with max dose constraints. A threshold deviation value was calculated to predict for 
patients needing mid-treatment replanning. This predictive model was applied to 52 patients 
treated at a separate institution. Dose was accumulated on 10 organs over 100 patients. To 
generate a threshold deviation that predicted the need to replan with 100% sensitivity, the 
submandibular glands required replanning if the delivered dose was at least 3.5Gy higher than 
planned by fraction 15. This model predicts the need to replan the submandibular glands with 
98.7% specificity. On the independent evaluation cohort, this model predicts the need to replan 
the submandibular glands with 100% sensitivity and 98.0% specificity. The oral cavity, 
intermediate CTV, left parotid, and inferior constrictor patients each had one patient exceeding 
the threshold deviation by the end of RT. By fraction 15 of 30-35 total fractions, the left parotid 
gland, inferior constrictor, and intermediate CTV had a dose deviation of 3.1Gy, 5.9Gy, and 
4.8Gy, respectively.  When a DIR failure was observed, the dose deviation exceeded the 
threshold for at least one organ, demonstrating that an automated DIR-based dose assessment 
process could be developed with user evaluation for cases resulting in dose deviations. A mid-
treatment threshold deviation was determined to predict the need to replan for the submandibular 
glands by fraction 15 of 30-35 total fractions of RT.   
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 Introduction   
 
Approximately 50,000 patients are diagnosed with head and neck (HN) cancer in the United 
States every year, with the incidence of human papillomavirus (HPV) – related cases rising 
[120]. Standard management includes chemotherapy plus radiation therapy. The combined 
chemoradiation is often so effective, especially for HPV+ patients, that their tumor often 
responds in volume over the course of treatment [121]. In addition, due to toxicities seen during 
treatment (i.e. mucositis), patients often lose weight during the course of chemoradiotherapy. 
These anatomical changes lead to deviations between the prescription (planned) dose and 
delivered dose, which are well documented for radiation therapy; however the majority of these 
studies used research software not immediately available for widespread clinical use [122-124]. 
Deviations call for plan modification during the fractionated treatment course for many head and 
neck cancer radiation treatment plans in order to ensure proper coverage of the tumor, to avoid 
overdosing of healthy tissue, and ultimately to ensure that the best treatment is delivered to the 
patient.    
 
Although some deviation between the planned and delivered dose is expected and not likely 
clinically significant, deviations that are clinically significant need to be identified early enough 
in the treatment delivery process to ensure that a plan adaptation can be safely performed to 
correct for the deviation. The need for adaptive replanning is often left to the discretion of the 
physician, and a quantitative model could aid in the decision to replan. Currently, there is no 
existing model to predict the need to replan and uncertainty exists as to what levels of deviation 
from the planned dose would result in a significant deviation from the initial expectations of 
tumor control and normal tissue toxicity risk. The goal of this work was to perform a quality 
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control study, using tools commercially available to determine the best estimate of the delivered 
dose across a large number of patients and then use this data to design a model to identify, by 
fraction 15 (out of 30-35 total fractions), which patients would complete treatment with a dose 
deviation exceeding the identified tolerance.  
 
 Methods and Materials  
 
4.3.1 Patient Data  
 
Data from 100 HN cancer patients treated with 30-35 fractions between November 2013 and 
October 2016 were retrospectively evaluated for this quality control IRB exempt evaluation. All 
patients were planned with volumetric modulated arc therapy (VMAT) using a commercial 
treatment planning system (Eclipse v13.6, Varian Medical Systems, Palo Alto, CA) and treated 
on a linear accelerator with daily kilovoltage cone beam CT (CBCT) imaging for pre-treatment 
positioning. Patient and treatment planning information is detailed in Table 1. CT-based 
treatment planning was performed based on the planning directive structures and goals listed in 
Table 2. The study focused on soft tissue organs at risk for toxicity that were within the field of 
view (FOV) of the CBCT.  
 
Table 4-1. Patient characteristics for all patients included in the study.  
Human papillomavirus is denoted as HPV. Clinical target volume is denoted as CTV. Planning target volume is 
denoted as PTV. Gross tumor volume is denoted as GTV.  
Table 1a. Patient Characteristics – Original patient cohort 
Patients (n) 100 
Gender (male/female) (n) 80/20 
Diagnosis site (n)  
     Pharynx 58 
     Larynx 21 
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     Lip and Oral Cavity  16 
     Other 5 
HPV status [positive/negative/unrecorded] (n)      59/13/28 
CTV [mean (range)] (cm^3) 154 (1-725) 
CTV to PTV margin (mm) 3 
Prescribed dose [mean (range)] (Gy)  68 (60-72)  
Fractions [35/30/other] (n) 66/17/17 
Patients with boost (n) 10 
Patients with replans (n) 16 
Elapsed Tx Time [median (range)] (days) 49 (39-74) 
IV contrast used in CT (Y/N) 78/22 
≥10% Weight Loss over entire Tx (n) 25 
≥5% Weight Loss over entire Tx (n) 67 
 
Table 1b. Patient Characteristics – Independent Evaluation set  
Patients (n) 52 
Gender (male/female) (n) 36/16 
Diagnosis site (n)  
     Pharynx 27 
     Sinonasal  12 
     Oral Cavity  5 
     Larynx 1 
     Other 7 
HPV status [positive/negative/unrecorded] (n)      10/10/32 
GTV [mean (range)] (cm^3)  45(4-171) 
Prescribed dose [mean (range)] (Gy)  67(60-70) 
Fractions [35/33/32/30] (n) 14/27/1/10 
Patients with boost (n) 13 
Patients with replans (n) 13 
 
 
Table 4-2. Planning directives for normal tissue structures used in the initial planning.  
The mean and max dose refers to the dose metric used for that organ. 
Table 2. Normal Tissue Structures and Goals  
Structure Target Value (Gy) 
Left/Right Submandibular Gland  Mean Dose < 30 
Larynx Mean Dose < 20 
Inferior Constrictor Mean Dose < 20 
Superior Constrictor Mean Dose < 50 
Oral Cavity Mean Dose < 30 
Left/Right Parotid Gland Mean Dose < 24 
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Spinal Canal Max Dose < 45 
 
4.3.2 Image Guided Radiation Therapy  
 
 
Daily image guided radiation therapy (IGRT) was delivered using automatic registration of the 
CBCT to the planning CT using a multiple iteration technique, with the initial iterations focusing 
on automated intensity based alignment of the entire planning CT and the CBCT and the final 
iterations focusing on the custom region of interest structure that was made from the union of the 
spinal canal and high-risk planning target volume (PTV). Manual adjustments were permitted 
following the automatic registration by the treating radiation therapist. The isocenter was defined 
on the planning CT to be at chin level to ensure the FOV of the CBCT scan covered the anatomy 
of interest.   
 
4.3.3 Calculation and Evaluation of Delivered Dose 
 
The daily CBCTs were directly accessible in the commercial treatment management software for 
DIR using a Demon’s-based contour propagation [101] and dose calculations (SmartAdapt, 
Varian Medical Systems, Palo Alto, CA). Figure 1 shows contours on the planning CT and the 
same contours propagated on the CBCT of a different fraction. Figure 2 shows the planned dose 
distribution and the recalculated dose on a daily CBCT. The calibrations between the CBCT and 
planning CT were matched using monthly measurements (QA) of standard materials with known 
electron density (Catphan®). The delivered dose at each fraction was calculated on the daily 
CBCT, and the dose was evaluated based on the propagated contours. 
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Figure 4-1. Contour examples.  
Example of contours at planning, fraction 10, fraction 20, and fraction 30 of one patient, showing the deformed 
structures.   
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Figure 4-2. Dose Distribution Examples.  
Example of the planning dose on the planning CT (top) and the dose distribution of the same plan calculated on the 
fraction 30 CBCT (bottom). 
 
The following dose metrics were calculated:  
 
Planned dose (DPlan) is the clinical prescription planned dose, based on the planning CT and 
original contours, calculated in the treatment planning software and exported for analysis and 
comparison with delivered dose.  
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Delivered (Fraction) dose (DFrac) for each fraction is the calculation of the clinical metric (e.g. 
mean or max dose) based on the dose calculated on the daily CBCT evaluated for the contours 
propagated from the planning CT onto the CBCT with DIR.  
 
Accumulated dose (DAcc) is the accumulation of clinical metric (DFrac) over all treatment 
fractions. As dose accumulation is not currently available in the commercial treatment planning 
system, the following approximation was made to estimate the accumulated dose. For mean dose 
metrics, the accumulation is performed by averaging the daily calculation of the mean dose.  For 
max dose metrics, the accumulation is performed by summing the daily calculation of the 
maximum dose, therefore representing the most conservative estimate (e.g. the highest max dose 
possible to a voxel). 
 
4.3.4 Model Development  
 
DPlan, DFrac for each fraction, and DAcc were all calculated for each patient’s treatment course. 
DAcc were calculated for each patient for fractions 1-5, 1-10, and 1-15, representing the 
accumulated dose to date up to fraction 5, 10, and 15, respectively, but scaled to the total number 
of fractions. That is, the Dacc at 1-5, 1-10, and 1-15 indicate the total dose that would be delivered 
if the entire treatment course was delivered as indicated by the first 5, 10, or 15 fractions. This 
scaling allows for direct comparison of dose deviations at each time point. Recently published 
data [125] suggests that a deviation between planned and delivered dose of less than 3.6Gy (15% 
of the 24Gy planning constraint) for parotid glands would not have a significant impact on the 
observed toxicity in a patient population. This 15% deviation criteria was then applied as a 
threshold for other HN organs with a mean dose constraint. This adaptive triggering model was 
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developed to identify dose deviations of 15% of the planning constraint of each organ at the 
completion of treatment early enough in treatment to enable corrective action. For CTVs, the 
dose deviation threshold was conservatively set at 7%, as the ICRU guideline [126] criteria is 
95% - 107% relative to the prescribed dose. Table 3 depicts the dose deviation threshold between 
planned and delivered dose for each organ.  
 
Table 4-3. Planning and dose deviation thresholds for the organs at risk and the target volumes.  
Prescription dose is denoted as Rx. The dose deviation threshold is based on 15% of the planning constraint for all 
tissue with the exception of the target volume and the spinal canal. The threshold for spine is based on the maximum 
clinical constraint being 48Gy [127]. 
Organ Dose 
Metric 
Planning 
Constraint [Gy] 
Dose Deviation 
Threshold [Gy] 
Inferior Constrictor  Mean 20 3 
Superior Constrictor Mean 50 7.5 
Spinal Canal Max 45 3 
High risk CTV D95% ±7% of Rx 4.10-5.18 
Intermediate risk CTV D95% ±7% of Rx 2.83-5.17 
Larynx Mean 20 3 
Oral Cavity Mean 30 4.5 
Left/Right Parotid glands Mean 24 3.6 
Left/Right Submandibular 
glands 
Mean 30 4.5 
 
 
Cases with a completed dose deviation to any structure that exceeded the structure-specific 
threshold were used to build a model to predict, with 100% sensitivity, whether a patient needs 
replanning, specifically looking at three time points: at the completion of fraction 5, fraction 10, 
and fraction 15. Each completed dose was compared to the planned dose to assess if the dose 
deviation threshold was exceeded for each organ for each patient. For every organ with a DAcc 
that exceeded the dose deviation threshold, the minimum deviations between the DPlan and DFrac 
for fraction 1, the average of fractions 1-5, 1-10, and 1-15 were assessed to find the minimum 
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deviation in delivered dose at that time point to indicate that replanning was necessary to avoid 
completing treatment with a deviation that exceeded the specified tolerance. In some cases, due 
to proximity of the disease, normal tissue could not be spared at planning, dose constraints were 
substantially exceeded, and replanning when dose is increased would not improve toxicity risk. 
Based on 5-year normal tissue complication probability (NTCP) curves for the parotid glands 
[128], toxicity risk was evaluated at the parotid gland planning constraint (a mean dose of 24Gy), 
at 34Gy, and 54Gy. A mean dose of 24Gy corresponded to 20% toxicity risk, 34Gy to 30%, and 
54Gy to 64%. As a 10Gy increase in mean dose corresponded to a 10% increase in toxicity, the 
model included organs with planned mean dose within 10Gy above the dose constraint, as we 
assumed that these patients could still benefit from replanning if the deviation in delivered dose 
exceeded the planned dose by more than the tolerance.  
 
4.3.5 Data Inclusion  
 
FOV and HU in CBCT was previously investigated demonstrating a 2% accuracy could be 
achieved with the exclusion of the superior 7mm and tissue in the shoulder region. The 
referenced study [91] compared dose calculations for the CBCTs and planning CTs of five 
oropharyngeal cancer patients undergoing radiation therapy. Rigid registration was performed 
between each CBCT and corresponding planning CT. CBCTs from the first three fractions of 
radiation treatment for each of the five patients included in the study were used for dose 
comparisons to measure the accuracy of dose calculation on CBCT. Three CBCT regions were 
assessed for dose calculation accuracy. Errors up to 80% were identified on the superior and 
inferior boundary of the CBCT. Errors were less than 2% after excluding the superior 7.1mm ± 
1.1mm extent of the CBCT and excluding the shoulder region in the inferior boundary. In the 
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current study, data was included only for organs on CBCT slices inferior to the superior-most 
7mm and for organs that were not missing material in the trapezius/shoulder region due to field-
of-view limitations. For the spinal canal, where Dmax was the metric of interest, the dose was 
evaluated only within the evaluable region of the CBCT. 
 
4.3.6 DIR Evaluation and Validation 
 
All DIR results were qualitatively evaluated using image fusion, evaluation of the deformation 
vector field (DVF), and visual assessment of the propagated structures onto the CBCT anatomy.  
For cases with DIR results identified as failing due to these qualitative metrics, the images were 
evaluated for artifacts. Images were re-registered to determine if a successful DIR result could be 
obtained.  If a successful DIR could not be obtained, the treatment fraction was excluded from 
analysis and the dose accumulation was scaled based on the number of fractions with accurate 
DIR. 
 
The assessment of DIR accuracy was based on contour propagation and comparison to manually 
drawn contours, therefore a baseline variation in the manual segmentation of normal tissues was 
established. Five HN patients were randomly selected for a reproducibility study. Segmentation 
of targets and critical organs was performed on four of the CBCTs by a radiation oncologist 
experienced in treating HN cancer and then a repeat segmentation was performed following a 
greater than two week time period, blinded to the original contours. The Dice similarity 
coefficient (DSC) was computed for the repeat contours for structures listed in Table 4.   
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The DSC calculates the overlap between two ROIs as defined by Eq. 4-1, and was used to assess 
the accuracy of the DIR based on the overlap between deformed and original contours.  
 𝐷𝑆𝐶 = 2
|𝐴 ∩ 𝐵|
|𝐴| + |𝐵|
   (4-1) 
 
Where A is the primary ROI, and B is the secondary ROI. Based on this equation, a DSC of 1 
indicates complete overlap, and a DSC of 0 indicates no overlap. The DSC was computed 
between the CT contours and CBCT contours propagated based on rigid registration alone and 
DIR.  
 
Table 4-4. Results of DIR validation study and CBCT contour reproducibility (mean and standard deviation).  
The p-value is based on a two-tailed paired Student’s T-test. Manual contour reproducibility was based on results of 
a resident radiation oncologist manually delineating structures on a CBCT, then repeating at a later date without 
reference to the original delineation. The submandibular glands are abbreviated to Sub. Glands in this table.   
 
Structure 
Registration Evaluation Manual Contour 
Reproducibility 
Rigid 
Registration 
DSC 
DIR DSC 
 
T-Test  
P-Value  
DSC 
Spinal Canal 0.81±0.04 0.85±0.03 < 0.01 0.93±0.02 
Sub. Glands  0.70±0.08 0.76±0.11 < 0.01 0.87±0.02 
Larynx 0.65±0.10 0.74±0.10 < 0.01 0.90±0.03 
Parotid Glands 0.64±0.09 0.71±0.08 < 0.01 0.78±0.05 
Sup. Constrictor 0.53±0.11 0.61±0.08 < 0.01 0.78±0.03 
Esophagus 0.41±0.10 0.58±0.09 < 0.01 0.63±0.18 
Inf. Constrictor  0.40±0.19 0.60±0.10 < 0.01 0.64±0.16 
 
4.3.7 Independent Model Validation 
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An independent validation was performed using a cohort of 52 patients treated at the MD 
Anderson Cancer Center whose dose was accumulated in a collaboration between the MD 
Anderson Cancer Center and the Netherlands Cancer Institute. Patient and treatment planning 
information is detailed in Table 1b. The original treatment plan was recalculated on the daily CT 
scans for each day of treatment, in order to calculate the delivered dose. The treatment isocenter 
was adjusted accordingly prior to dose recalculation. Using a deformation vector field (DVF) 
from DIR (Admire 1.04, Elekta AB, Stockholm, Sweden), the new dose distribution was mapped 
to the planning CT. The daily dose to each organ was calculated using the original contours on 
the planning CT. In the case of missing daily CTs, linear interpolation was performed on the CTs 
of the two closest fractions in order to create the missing fractionated doses. Nearest neighbor 
extrapolation was performed in the case that the daily CT from the first or last fraction was 
missing. The predictive model was applied to the delivered dose to 104 submandibular glands at 
fraction 15. The validation of the predictive model using this external data set was evaluated 
based on the dose deviation threshold set at 15% of the planning constraint (4.5Gy). 
 
 Results  
 
Of the 3291 DIRs performed on 100 patients, 1% failed. These failures were due to metal 
artifact, beam hardening artifact, shadowing, and lack of contrast on the CBCTs. The maximum 
number of DIR failures for a single patient was 3. In the cases with DIR failures a deviation from 
the planned dose of greater than 15% was observed for at least one organ. DIR failures led to the 
re-registration of images, however that did not result in DIR improvement. Data due to errors in 
dose calculations and DIR were excluded from further analysis.      
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4.4.1 Contour Reproducibility and DIR Validation 
 
Table 4 shows the results of the DIR validation and CBCT contour reproducibility. DIR 
improved DSC over rigid registration for 100% of inferior constrictors, 94% of esophagi and 
parotid glands, 90% of submandibular glands, and 75% of superior constrictors, spinal canals, 
and larynges included in the study. Based on a two-tailed paired Student’s T-test, improvement 
in DSC was statistically significant from rigid registration to DIR in all organs. The average DSC 
over all CBCTs included in the study is included in the table for both the rigid registration and 
the DIR.  
4.4.2 Dose Deviation Threshold 
 
The results of setting a 15% dose deviation threshold at treatment completion are shown in Table 
5. There was one patient exceeding the threshold for oral cavity, left parotid gland, intermediate 
CTV, and inferior constrictor, and the average deviation between Dplan and DFrac is reported for 
the completion of treatment and fraction 15. For the submandibular glands, where 7 patients 
exceeded the threshold, the maximum deviation at completion of treatment and minimum 
deviation by fraction 15 are shown.   
 
Table 4-5. Number of organs with clinically relevant dose deviations and values of those deviations.  
The total number of organs were those that originally had dose calculations done for the study. The organs included 
in the model were those within the evaluable region of the image and not on images for which DIR failures were 
observed. 
Organ Planning 
Constraint 
[Gy] 
Dose 
Deviation 
Threshold 
[Gy] 
Total 
Number 
of 
Organs 
Organs 
Included 
in Model 
Organs 
Exceeding 
Deviation 
Maximum 
Deviation at 
Completion 
of Tx [Gy] 
Minimum 
Deviation 
by Fx15 
[Gy] 
Spinal Canal 
 
45 3 99 99 1 3.1 NA 
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Left/Right 
SGs 
30 4.5 176 85 7 8.22  3.5 
Sup. 
Constrictor 
50 7.5 100 60 0   
Oral Cavity 
 
30 4.5 100 56 1 5.18 0.81 
High CTV 
 
±7%*Rx 4.10-5.18 103 43 0   
Left Parotid 
 
24 3.6 100 37 1 3.77 3.08 
Right Parotid 24 3.6 99 34 0   
Int. CTV 
 
±7%*Rx 2.83-5.17 101 17 1 -6.65 -4.84 
Inf. Const 
 
20 3 97 12 1 5.62 5.86 
 
 
The left and right submandibular glands were combined into a single model to account for all 
patients with completed dose deviations exceeding the threshold. Eighty-five total 
submandibular glands were without DIR failures and in the evaluable region of CBCTs. With a 
dose deviation threshold set at 15% of the planning constraint (4.5Gy), seven submandibular 
glands exceeded the threshold. By fraction 15, the minimum deviation of these seven glands, 
using the Dacc at fraction 15 scaled to the total delivered dose, was 3.5Gy (maximum = 7.1Gy, 
median = 5.1Gy, mean = 5.3Gy). This minimum deviation threshold was set for each time point 
of treatment to evaluate predictive power for final dose deviation.  The resulting false positives, 
sensitivities, specificities, and positive and negative predictive values (PPV and NPV) are shown 
in Table 6.  Out of the 12 patients with evaluable inferior constrictor dose deviations, one had a 
potentially clinically significant dose deviation of 5.6Gy at completion of treatment. This 
deviation, and the need to replan, was predicted by fraction 15, with a dose deviation of 5.86Gy. 
 
Table 4-6. Model based on submandibular glands (SG).  
The minimum dose deviation for Fx 1-15, 1-10, 1-5, and 1 is based on the minimum dose deviation by fraction 15 
that leads to a dose deviation exceeding the dose deviation threshold at completion of treatment. CI refers to 
confidence interval. Dev. refers to deviation.  
Organ Total 
SGs 
(N) 
Dose 
Deviation 
Threshold 
[Gy] 
Organs 
Exceeding 
Dose 
Deviation 
Test  Fx 1-15 
Dose 
Dev. 
[Gy] 
95% CI Fx 1-10 
Dose 
Dev. 
[Gy] 
Fx 1-5 
Dose 
Dev. 
[Gy] 
Fx 1  
Dose 
Dev. 
[Gy] 
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Threshold 
 
 
 
 
L/R 
SGs 
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4.5 
 
 
 
 
7 
Min. 
[Gy] 
3.5  3.5 3.5 3.5 
False 
Pos. 
1  3 2 10 
Sens. 1.00 0.59, 1.00 100 57.1 28.6 
Spec. .99 0.93, 1.00 96.2 97.4 87.2 
PPV .88 0.47, 1.00 70 66.7 16.7 
NPV 1.00 0.95, 1.00 100 96.2 93.2 
 
 
Of the 17 patients with evaluable intermediate CTV dose deviations, one had a potentially 
clinically significant dose deviation of -6.7Gy at the completion of treatment. This deviation, and 
the need to replan, was predicted by fraction 15, with a dose deviation of -4.8Gy. 
 
Of the 56 patients with evaluable oral cavity dose deviations, one had a potentially clinically 
significant deviation of 5.2Gy. However, the early treatment fractions did not show clinically 
relevant dose deviations, and therefore did not predict the final dose deviation. By fraction 15, 
the dose deviation was only 0.81Gy. 
 
Of the 99 patients with evaluable spinal canal dose deviations, one had a potentially clinically 
significant deviation of 4.3Gy, leading to a Dacc of 48.1Gy, which exceeds the maximum 
planning constraint. Therefore, trends could not be evaluated for this organ.   
 
4.4.3 Independent Model Validation 
 
On the independent validation data set, four submandibular glands exceeded the dose deviation 
threshold by the end of treatment. By fraction 15, a total of six glands exceeded the 3.5Gy 
minimum deviation based on the original dataset; four of these glands were those that exceeded 
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the 4.5Gy deviation threshold by the end of treatment. Independent validation predicted the dose 
deviation threshold by the end of treatment with 100% sensitivity (95% CI: 40%, 100%), 98% 
specificity (95% CI: 93%, 100%), 67% PPV (95% CI: 22%, 96%) and 100% NPV (95% CI: 
96%, 100%).  
 
 Discussion  
 
A deviation threshold was developed from a large cohort of patients to aid physicians in the 
decision to replan HN cancer patients. This replanning strategy has the potential to impact HN 
cancer patients by automatically identifying cases that could benefit from replanning by the 
midpoint of treatment. Treatment planning and CBCT image data from 100 HN patients were 
retrospectively analyzed to build a model to predict clinically relevant deviations between 
planned and delivered dose. For these 100 patients, 9 HN organs of interest were evaluated over 
30-35 fractions of VMAT. If a mean dose deviation threshold of 3.5Gy is set by fraction 15 for 
the submandibular glands, the need for replanning can be predicted with 98.7% specificity 
providing 87.5% PPV, and 100% NPV. Applying this model to an independent validation set 
from a different institution using a different DIR algorithm predicted the need for replanning 
with 100% sensitivity, 98% specificity, 67% PPV and 100% NPV. The inferior constrictor, 
intermediate CTV, oral cavity, and left parotid glands only had one patient exceeding the 
corresponding dose deviation threshold by the end of treatment. With the exception of the oral 
cavity, all of these patients would be flagged by fraction 15 of treatment using this model.  
Trends could not be evaluated for spinal canal as only one patient had a substantial deviation. 
The spinal canal was used for initial alignment of the CBCTs to CTs, likely influencing 
consistent delivery of planned dose. 
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As demonstrated in Table 6, the confidence intervals for specificity are relatively narrow 
(resulting from the majority of subjects not requiring replanning), while the confidence intervals 
for sensitivity are relatively wide (since the number of positives, i.e., subjects requiring 
replanning, is small in both cohorts). Although the model achieves 100% sensitivity, it’s difficult 
to make strong statistical claims due to the limited number of cases that require replanning, 
indicating the need to further validate this model in a prospective clinical trial. Assuming that the 
true proportion of observations requiring treatment replanning is 8%, a minimum sample size of 
100 subjects will be required to achieve ≥ 80% power to reject the null hypothesis that the 
sensitivity is ≤ 70% under the alternative that the sensitivity is ≥ 98%, using an exact test for a 
single proportion with one-sided significance level 0.05. This sample size is also sufficient to 
detect a change in the value of specificity from 85% to 95% (assuming 92 plans do not require 
replanning), also using a one-sided test with level 0.05. 
 
Although true dose accumulation using an accurate DIR method is ideal, it has been shown [129] 
that the population differences are small (the difference between the population average of mean 
PG doses and the population average of DIR mean PG doses was 0.3Gy) and did not impact the 
assessment of replanning strategies. This study used manual delineations on CT and used those 
contours for DIR and to propagate the dose. The current study used DIR between CT and CBCT 
to propagate the contours, which could potentially increase uncertainties in the estimated 
delivered dose. The impact of uncertainties in the DIR algorithm on the assessment of delivered 
dose requires further investigation. Limited data exists in the literature on how uncertainties in 
DSC translate to uncertainties in dose. A recent study reported on the impact of the accumulated 
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minimum dose as a function of variation in DIR [130]. This study demonstrated that, in order to 
impact the minimum dose, a combination of low contour DSC in a high dose gradient would 
have to occur. A maximum difference of 2.5 Gy in the minimum dose was observed. The current 
study reported on the mean dose to each organ and would therefore be less sensitive to low DSC 
and high dose gradients.     
 
Substantial DIR error occurred in a limited number of cases, 1%, and was attributed to artifact, 
shadowing effects, beam hardening artifact, shadowing, and lack of contrast on the CBCTs. The 
potential to develop a completely automated dose accumulation process is limited by the 
possibility of DIR errors and the potential need to evaluate the results in real time. Dose 
deviations from all cases with substantial DIR failure were evaluated and all of them were found 
to lead to reported dose deviations of greater than 15% between planned and delivered dose for 
at least one organ.  This data suggest that it may be possible to develop an automated process and 
perform DIR evaluation only on those cases that result in a dose deviation greater than 15% 
(10% of cases).  This requires further testing on additional patients.      
 
A previous study [91] determined that FOV differences between CT and CBCT lead to dose 
calculation error up to 80% on the superior and inferior edge inside the CBCT FOV. For dose 
calculations to not exceed 2% error, organs in the superior 7mm and the shoulder regions of the 
CBCTs were excluded in evaluations. Future work must address this limitation to ensure a robust 
method is available to calculate the daily dose to all structures of interest. Augmenting the 
missing data from the CT or deforming the CT to the CBCT are potential methods to improve 
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these dose calculations.  
 
The dose deviation threshold was based on research that stated that dose changes of less than 
3.6Gy (15% of the planning constraint) to parotid glands would not have a significant impact in a 
population. As similar data for other soft tissue structures with mean dose constraints does not 
exist, this 15% was applied as the dose deviation threshold for the other HN organs with mean 
dose planning constraints evaluated in this study. However, consensus on a clinically meaningful 
dose deviation has not been reached across the radiation oncology community.   
 
 Conclusion  
 
In this study, a predictive model was developed to aide physicians in the decision to replan HN 
patients undergoing radiation therapy. This is the first model developed for this purpose, and was 
validated on an external validation patient cohort. While this model was developed with 100% 
sensitivity (e.g. to catch all patients exceeding a clinically significant dose deviation threshold) 
on the original patient cohort, it also predicted the need to replan with 100% sensitivity on the 
external validation patient cohort. Using this model in the clinic provides physicians with the 
first predictive model to aide in the decision to replan HN patients undergoing radiation therapy. 
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Chapter 5. Biomechanical Modeling of Neck Flexion for 
Deformable Alignment of the Salivary Glands in Head and Neck 
Cancer Images 
 
Patients undergoing radiation therapy for HN cancer often receive imaging in different positions. 
The patient may be setup differently in the diagnostic image, planning image, treatment images, 
and follow-up images. In order to map contours from one image to another, proper alignment 
must be completed between the two images. Currently, rigid registration and intensity-based 
deformable image registration is used clinically, in order to register two images and map the 
contours from one image to the other. However, rigid registration alone may not account for the 
changes in the tissue, and intensity-based registration methods may not allow us to see the 
changes inside the individual organs. Additionally, intensity-based registration methods do not 
allow for the extrapolation of contours outside of the image FOV, as investigated in the previous 
chapter. This work investigates a biomechanical model-based deformable image registration 
method to align the salivary glands, based on the varying angles of neck flexion of patients 
undergoing HN radiation treatment.   
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 Abstract 
 
During head and neck (HN) cancer radiation therapy, analysis of the dose-response 
relationship for the parotid glands (PG) relies on the ability to accurately align soft tissue 
organs between longitudinal images. In order to isolate the response of the salivary glands 
to delivered dose, from deformation due to patient position, it is important to resolve the 
patient postural changes, mainly due to neck flexion. In this study we evaluate the use of a 
biomechanical model-based deformable image registration (DIR) algorithm to estimate the 
displacements and deformations of the salivary glands due to postural changes. A total of 
82 pairs of CT images of HN cancer patients with varying angles of neck flexion were 
retrospectively obtained. The pairs of CTs of each patient were aligned using bone-based 
rigid registration. The images were then deformed using biomechanical model-based DIR 
method that focused on the mandible, C1 vertebrae, C3 vertebrae, and external contour. 
For comparison, an intensity-based DIR was also performed. The accuracy of the 
biomechanical model-based DIR was assessed using Dice similarity coefficient (DSC) for 
all images and for the subset of images where the PGs had a volume change within 20%. 
The accuracy was compared to the intensity-based DIR. The PG mean (STD) DSC were 
0.63 (0.18), 0.80 (0.08), and 0.82 (0.15) for the rigid registration, biomechanical model-
based DIR, and intensity based DIR, respectively, for patients with a PG volume change up 
to 20%. For the entire cohort of patients, where the PG volume change was up 57%, the 
PG mean (STD) DSC were 0.60 (0.18), 0.78 (0.09), and 0.81 (0.14) for the rigid 
registration, biomechanical model-based DIR, and intensity based DIR, respectively. The 
difference in DSC of the intensity and biomechanical model-based DIR methods were not 
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statistically significant when the volume change was less than 20%. When the volume 
change was large, there was a significant difference, although the magnitude was small. 
These results demonstrate that the proposed biomechanical model with boundary 
conditions on the bony anatomy can serve to describe the varying angles of neck flexion 
appearing in images during radiation treatment and to align the salivary glands for proper 
analysis of dose-response relationships. It also motivates the need for dose response 
modeling following neck flexion for cases where parotid gland response is noted. 
 
 Introduction 
 
During external beam radiation therapy (EBRT) of head and neck (HN) cancer, dose to the PG 
can lead to toxicity [32]. Studies have shown that limiting the mean dose to the salivary glands 
during HN radiation therapy leads to lower toxicity to the patient [131]. However, preclinical 
studies show that considering specific subregions of the glands could improve dose response 
modeling [74]. Understanding the effect of the dose to the subregions of the glands over the 
course of radiotherapy is challenging due to the volumetric response combined with the sharp 
dose gradient within the glands. Determining the dose to subregions over the course of treatment 
requires spatial alignment of longitudinal images. Deformable registration of the gland is 
challenging due to the volumetric response, deformation, and the uniform contrast of the glands 
on CT images which remain the standard imaging modality in the radiation therapy workflow. 
 
The majority of techniques proposed for DIR of longitudinal images of HN cancer patients use 
intensity-driven algorithms to deform one image so that the structure boundaries match those in 
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the other image [132-135]. Using these conventional DIR approaches, the estimated 
deformations inside PGs will only depend on the displacement vector field (DVF) regularization 
model of the DIR algorithm. However, the shrinkage scheme is likely more complex, correlating 
to the heterogeneity of the dose inside the organ and potentially the sensitivity of the local 
structure within the gland. Biomechanical model-based DIR algorithms allows exploration of 
such complex deformations and volume change as the PGs respond to radiation therapy. Early 
work by Al-Mayah demonstrates that the use of dose-based boundary conditions in a 
biomechanical models can simulate the radiation dose response during HN radiation therapy 
[136].     
 
Based on the above study, biomechanical model-based DIR provides the potential to investigate 
the PGs response to radiation. However, in order to understand the PG response to radiation dose 
other sources of displacements and deformations of the glands should be resolved first. In 
particular, flexion of the neck or movement of the mandible are often observed between images 
acquired at different time points because of the difficulty in reproducing the patient position in 
the presence of weight loss or when acquisition is performed by different imaging devices, 
limiting the consistency of immobilization devices. In order to accurately model the volumetric 
changes of the PG subregions due to dose-response during radiation therapy, an initial alignment 
of the PGs is necessary to first resolve the changes due to neck flexion. A previous feasibility 
study [137] investigated a biomechanical model of the HN with various boundary conditions. 
This study found that the highest accuracy, based on the DSC of the tumor and PGs, was found 
when placing boundary conditions on the vertebrae and mandible. However, the evaluation was 
tested on a small dataset of four pairs of images and requires further validation. 
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The goal of this study is to perform a comprehensive investigation and validation of the use of 
biomechanical model-based registration to resolve the misalignment of the salivary glands only 
due to those postural changes and compare to an intensity-based DIR method for a large cohort 
of patients demonstrating a range of levels of volumetric response of the parotid gland. The use 
of a commercially available biomechanical model of the patient anatomy with boundary 
conditions on relevant bones and external contours is proposed. For evaluation of the model, a 
cohort of 82 patients was retrospectively evaluated and for each patient a pair of CT scans 
presenting noticeable differences in the angle of neck flexion was selected. The overlap between 
mapped deformed gland volumes and original gland volumes were measured after solving the 
neck flexion using the biomechanical model-based DIR algorithm. In order to assess the 
accuracy of the biomechanical approach to resolve patient positioning, the performances of the 
biomechanical approach were compared to the performances of the rigid and intensity-based DIR 
methods for PGs with volume change within 20%, to evaluate the accuracy of alignment when 
little response is noted, as well as the whole cohort of patients, with volume change up to 57%, 
to evaluate the need of further dose-based boundary conditions on the glands when response is 
noted.  
 
 Methods 
 
 Patient Data  
 
A retrospective IRB approved evaluation was performed on 164 PG from 82 oropharynx cancer 
patients who underwent EBRT. For each patient, two non-contrast enhanced CTs showing neck 
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flexion acquired on different dates were selected. The normal tissue structures were previously 
auto-segmented (Admire ABAS, Elekta, Stockholm, Sweden) on all images. For this study, all 
images and contours were imported into a TPS with biomechanical model-based deformable 
registration capabilities (RayStation v6.99, RaySearch Laboratories, Stockholm, Sweden).  
 
 
Figure 5-1. Examples of rigid registration performance for three cases.  
The top row shows the primary images, the middle row shows the secondary images, and the bottom row shows the 
rigid registration results (with focus on skeletal anatomy) between the primary and secondary images.  
 
 
5.4.1 Image registration 
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The following registration and evaluation steps were performed automatically for all 82 patients 
using a Python-based script in the TPS. 
 
 
Rigid Registration. For each patient, gray level-based rigid registration was performed in the 
TPS between the two CTs displaying neck flexion using a focus on the skeletal anatomy. This 
registration step served as the initial registration for the DIR that followed. Examples of the rigid 
registrations are illustrated in Fig. 1. The bottom row of Figure 3 shows the overlay of the 
images after a global rigid registration based on all bony anatomy. On the left column both the 
vertebra and mandible were still misaligned. For the case in the middle column only the vertebra 
were still misaligned while for the third case only the mandible was still misaligned. It is 
expected that a biomechanical model driven by boundary conditions on the vertebrae and 
mandible would allow a better global alignment particularly for the PG.  
 
Deformable Image Registration. Following the initial rigid registration, both intensity and 
biomechanical-based DIRs were performed between the CTs of each patient. The intensity-based 
DIR algorithm used in this study was the ANAtomicaly CONstrained Deformation Algorithm 
(ANACONDA) implemented in the commercial TPS (RayStation v6.99, RaySearch 
Laboratories, Stockholm, Sweden). For the ANACONDA method, the registration problem is 
represented as a nonlinear optimization problem, where the objective function is defined as f : Rn 
→ R , and R is there reference image. The equation for the nonlinear optimization problem is 
 
 𝑓(𝑣) =  𝛼𝐶(𝑣) + (𝛽𝐻(𝑣) + 𝛾𝑆(𝑣)) + 𝛿𝐷(𝑣)   (5-1) 
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where non-negative weights are represented by α, γ, and δ, C(𝜈) represents the correlation 
coefficient, the term βH(𝜈) allows coordinate functions to minimize (approximately) the 
Dirichlet energy and causes the invertibility and smoothness of the DVF,  γS(𝜈)  penalizes large 
ROI deviations (together, βH(𝜈) + γS(𝜈) control regularization of the deformation grid), and D(𝜈) 
includes ROIs that guide the deformation (in the case that the user has selected any). A smooth 
DVF is optimized using the quasi-Newton algorithm.  Similarity between the images is 
determined by correlation coefficients, which guide the DVF. Regularization is attained with 
minimization of the weighted Dirichlet energy for coordinate functions of the DVF, and involves 
first resolving the DVF smoothness and invertibility, and then penalizing large deviations in the 
regions of interest (ROI). Controlling ROIs can be chosen by the user to guide the DIR, but were 
not selected in this study when using the algorithm. .  
 
The biomechanical model-based DIR algorithm used for this study was the commercial 
implementation of Morfeus [63] in the TPS. Briefly, Morfeus creates tetrahedral meshes from 
the contours of the body and organs included in the model and assigns elastic properties to each 
of them. For each organ, a surface projection method between the organ surface on the reference 
and secondary images determines the displacement of the surface nodes of the tetrahedral 
meshes. Those displacements are used as boundary conditions in the model to solve the 
displacement of all the internal mesh nodes in a finite-element analysis. In the proposed model, 
boundary conditions were applied on the mandible, C1 vertebrae, and C3 vertebrae, as well as 
the patient external contour. These boundary conditions were chosen for their proximity to the 
PG, and their capacity to describe most possible postural changes. 
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5.4.2 Registration evaluation 
 
Based on the rigid registration and two DIR methods (intensity and biomechanical), the left and 
right PG segmentations were propagated from the CT0 (the earlier dated CT) to CT1 (the later 
dated CT). The performance of each method to accurately propagate the PG structures were 
reported using the following metric: 
Dice Similarity Coefficient. The DSC, which calculates the overlap between two ROIs as 
defined by Eq. 1, was used to assess the accuracy of the DIR based on the overlap between 
deformed and original contours.  
 𝐷𝑆𝐶 = 2
|𝐴 ∩ 𝐵|
|𝐴| + |𝐵|
   (5-2) 
 
Where A is the primary ROI, and B is the secondary ROI. Based on this equation, a DSC of 1 
indicates complete overlap, and a DSC of 0 indicates no overlap. The DSC was calculated in the 
TPS for the left and right PG, individually, based on the rigid registration, intensity-based DIR 
method, and the biomechanical model-based DIR method. For each case, the DSC was 
calculated between the deformed ROI mapped on the second CT and the original ROI on that 
CT. The mean DSC for PG variability (based on multiple observers) is 0.76 [138].  
 
Volume Change. The volume of the left and right PG from each CT were calculated in the TPS 
in order to understand the analysis of the PG DSC. The DSC from the intensity-based DIR and 
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the biomechanical model-based DIR were evaluated in cohorts based on absolute percent volume 
change of the PG. A two-tailed paired Student’s T-test was used to assess the statistical 
significance between the PG DSC of each DIR method for cases with volume change within 
20% and for the entire cohort. The DSC as a function of volume change is important as the 
intensity based registration should account for volume change, whereas the biomechanical based 
registration does not have boundary conditions on the PGs and therefore will not account for 
volume change (e.g. when the 2 images represent both neck flexion and PG volume chance, the 
biomechanical model, by definition, will only account for the neck flexion and the volume 
difference should be noted by a DSC less than 1).  
 
DSC for cases with less than 20% volume change using biomechanical-based DIR will evaluate 
the accuracy and robustness of the algorithm to resolve the deformation and positional changes 
due to neck flexion.  The DSC for cases with more than 20% volume change will evaluate the 
accuracy and robustness of the algorithm to partially resolve complete deformation, but highlight 
the potential need for further boundary constraints to resolve the volumetric response.  The DSC 
for the intensity-based DIR will indicate the accuracy and robustness of the algorithm to resolve 
this complex deformation. 
 
 Results 
 
Table 1 shows the mean, standard deviation (STD), maximum, and minimum DSC of the PG 
over all patients with volume change within 20% (N=63). The intensity-based DIR method 
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resulted in a slightly higher mean DSC average (0.02) and slightly higher standard deviation 
(0.07) at (0.82±0.15) than the biomechanical model-based DIR method (0.80±0.08), and both 
DIR methods resulted in a higher mean DSC and lower standard deviation than rigid registration 
(0.63±0.18). No significant differences were observed (p = 0.13) between the DIR methods and 
both methods had a DSC greater than the DSC reported for inter-observer variation (0.76). The 
minimum PG DSC were 0.17 and 0.53 for the intensity-based and biomechanical model-based 
DIR methods, respectively, indicating the potential for more ‘catastrophic’ registration errors 
with the intensity-based algorithm. The maximum PG DSC were 0.96 and 0.93 for intensity-
based and biomechanical model-based, respectively.  
 
Table 5-1. Registration method comparison according to PG DSC.  
For each method, the mean, STD, max, and min DSC values of the PG are reported. The percentage of patients with 
a DSC superior to 0.75 are also reported.  
DIR 
method 
Mean STD Min 
 
Median Max 
% of PG 
with DSC 
> 0.75 
Rigid 0.63 0.18 0.07 0.66 0.94 20% 
Intensity-
based 
0.82 0.15 0.17 0.87 0.96 80% 
Biomechan
ical model-
based 
0.80 0.08 0.53 0.82 0.93 76% 
 
 
Figure 2 is a histogram depicting the number of PG with DSC greater than values ranging from 0 
to 1. All PG (n=87) resulted in DSC greater than 0.1 for both methods, and 0 PG resulted in DSC 
greater than 0.95. Twenty-four (28%) PGs had a DSC that exceeded 0.9 for the intensity-based 
method, while only 8 (9%) PG exceeded 0.9 for the biomechanical model-based method. 
However, all of the biomechanical model-based registrations had a DSC of 0.5 or greater, 
whereas 84 of the intensity-based registration had a DSC of 0.5 or greater.  
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Figure 5-2. PG DSC Histogram.  
Histogram depicting the number of PG with DSC greater than the corresponding value, ranging from 0 to 1. The 
results of the intensity-based DIR method is depicted in blue and the results of Morfeus are depicted in orange, for 
patients with <20% volume change.  
 
Table 2 shows the mean, standard deviation (STD), maximum, and minimum DSC of the PG 
over all patients. The intensity-based DIR method resulted in a slightly higher mean DSC 
average (0.03) and slightly higher standard deviation (0.05) at (0.81±0.14) than the 
biomechanical model-based DIR method (0.78±0.09), and both DIR methods resulted in a higher 
mean DSC and lower standard deviation than rigid registration (0.60±0.18). Similar to the subset 
evaluated above, both DIR algorithms had an average DSC greater than the inter-observer 
variability (0.76). 
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Table 5-2. Registration method comparison according to PG DSC.  
For each method, the mean, STD, max, and min DSC values of the PG are reported. The percentage of patients with 
a DSC superior to 0.75 are also reported.  
DIR method Mean STD Max Min 
% of PG with 
DSC > 0.75 
Rigid 0.60 0.18 0.94 0.07 21% 
Intensity-
based 
0.81 0.14 0.96 0.17 77% 
Biomechanical 
model-based 
0.78 0.09 0.93 0.53 67% 
 
 
Including cases where the volume change exceeded 20%, the differences in DSC between the 
intensity-based DIR and biomechanical model-based DIR becomes statistically significant. The 
significant difference between the PG DSC in cases with a 20% volume change demonstrates the 
need for additional boundary conditions to describe this volumetric response. The larger STD 
and lower minimum DSC of the intensity-based registration demonstrates the potential 
advantage of the biomechanical model-based approach when potentially combined with a dose-
based boundary condition on the PGs. Figure 3 illustrates the range of DSC for each method as a 
function of volume change. 
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Figure 5-3. DSC Boxplots.  
Boxplots of the DSC obtained for rigid registration (gray), intensity-based DIR (orange), and biomechanical model-
based DIR (blue) for different volume changes of the DSC obtained for the propagated PG contours based on each 
DIR method. PG 5 represents volume change of 5%, and the same for other values. Outliers are shown in the 
bubbles below each box plot. Median DSCs are represented by the horizontal lines, the lower whiskers represent the 
minimum, the upper whiskers represent the maximum, the base of the box represents the lower quartile, and the 
ceiling of each box represents the upper quartile. Intensity-based and biomechanical model-based results are shown 
in pairs for each volume change threshold.  
 
 Discussion  
 
In this study, we retrospectively evaluated the registration of 82 repeat CT scans for 
oropharyngeal cancer using the DSC between the deformed and original delineations of the PGs. 
For each set of CT scans, DIR was performed using intensity-based registration for full image 
DIR and a biomechanical model-based methods focused only on resolving the neck flexion, and 
therefore PGs with minimal volume change were evaluated in an isolated cohort.  
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There was no statistically significant difference observed between the DIR methods for cases with 
a PG volume change within 20%, and both DIR methods had a median DSC of greater than the 
inter-observer variation. Additionally, the clinical significance of a 0.02 decrease in mean DSC is 
arguably minimal. The standard deviation for the intensity-based method was larger than for the 
biomechanical model-based method and the minimum DSC was lower, indicating more potential 
failures in the results of the intensity-based method, which was further demonstrated by 3 PGs that 
had a DSC of less than 0.5 following intensity-based DIR.  
 
This data demonstrates that modeling neck flexion alone using a biomechanical model-based 
registration algorithm aligns the PGs as accurately as an intensity-based registration and within 
the expected contour variation. For a volume change exceeding 20%, the results of each method 
were statistically significant, as expected given the lack of boundary conditions driving the 
alignment of the PGs in the biomechanical model. Future work will include applying dose-based 
boundary conditions to the biomechanical model-based algorithm [136] in order to build a 
comprehensive model that involves accurate neck flexion as well as a deformation model function 
of the dose distribution in the PG.   
 
Evaluation of the DSC trends showed that there are 10 outliers in the total 164 PGs for the 
intensity-based method and 0 for the biomechanical model-based method. This indicates more 
failures in the intensity-based method. Table 2 shows the minimum DSC over all patients for the 
intensity-based method was 0.17, while the minimum DSC for biomechanical model-based 
method was 0.53. This data suggests that for challenging cases where intensity-based methods fail, 
even a simple biomechanical model-based method may give reasonable results.  
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 Conclusion 
 
In this study, a biomechanical model was developed to align the parotid glands based on changes 
only due to the varying angles of neck flexion of HN patients undergoing radiation therapy. For 
patients with minimal volume change in the parotid glands, and therefore changes only due to the 
position of the patient, the biomechanical model-based deformable image registration algorithm 
performed alignment of the parotid glands with indistinguishable results from the intensity-based 
method. Which the results of this study, it is known that biomechanical modeling with minimal 
boundary conditions can be used to resolve the neck flexion in images of patients undergoing 
radiation therapy for HN cancer. This model can be applied to patients with follow-up imaging 
done in different positions than during planning, allowing for the propagation of contours to map 
the tumor and normal tissue. Additionally, this model could be applied when the need arises to 
map contours outside of the field of view of the image, as in the work in the previous chapter. 
 112 
Chapter 6. Biomechanical Modeling of Dose-Induced Volumetric Changes of 
the Parotid Glands for Deformable Image Registration 
 
Current toxicity models for head and neck cancer are based on the mean dose to the entire gland, 
however recent studies [74] have shown that toxicity to the parotid gland may be more closely 
related to the dose to the substructures. Normal tissue structures deform through radiation 
therapy, due to the varying angles of neck flexion, weight loss, and dose-response. The last study 
resolved the deformation due to the varying angles of neck flexion, using a biomechanical 
model-based deformable image registration algorithm with optimal bony anatomy boundary 
conditions (C1 vertebra, C3 vertebra, and mandible). With the application of this initial 
registration, the addition of dose-based boundary conditions should resolve the remaining 
deformation. There first exists the need to determine the volumetric response of the parotid 
glands to radiation therapy, and study the response of the substructures of the glands. In this 
study, biomechanical models of the parotid gland response to radiation therapy are developed, by 
employing thermal expansion coefficients modified to describe the dose delivered and the 
resulting volumetric response.  
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 Abstract  
A major side effect of radiation treatment for head and neck cancer is xerostomia, which leads to 
a poor quality of life. Current toxicity models for the parotid glands are based on mean dose to 
the entire gland, however recent small animal studies show that there may be a better correlation 
between the radiation dose to the sub-regions of the parotid glands and the risk of toxicity. 
Delivered dose to the parotid gland sub-regions can be estimated with dose accumulation using 
deformable image registration. The purpose of this study was to build a population model 
describing the relationship between radiation dose and parotid gland shrinkage and to use this 
model to aide in the improvement of deformable image registration accuracy of head and neck 
images during radiation therapy. A modified thermal-expansion coefficient was determined 
based on the population model and served to apply shrinkage to each element of the finite 
element model based on the planned dose. Based on the thermal-expansion coefficient, dose-
based boundary conditions were applied to an in-house biomechanical model-based deformable 
image registration algorithm. Assessment of the accuracy of the model was based on target 
registration error (TRE). The accuracy was improved significantly (p = 0.01) from a TRE of 1.6 
± 0.9 mm for the standard model to a TRE of 1.4 ± 0.8 mm for the proposed model. Application 
of these models may allow better estimation of the delivered dose during radiation therapy and 
aide in the development of improved toxicity prediction models.  
 
 Introduction  
 
Over 550,000 new cases of head and neck (HN) cancer are diagnosed leading to 380,000 deaths 
per year in the United States [139]. Most HN cancers recommended management include radiation 
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therapy. While treatment planning aims to avoid irradiation of the salivary gland to preserve their 
function, a total sparing is rarely achievable. A major side effect of the parotid gland (PG) 
irradiation is Xerostomia, which is defined as oral dryness [140]. Xerostomia leads to dysphagia, 
or difficult swallowing, which lowers the quality of life (QoL) substantially. A better sparing of 
the PG may improve the QoL of HN cancer patients [131]. Currently, prediction of toxicity for the 
PG is based on the mean dose to the entire gland. However, small animal studies show that the 
relationship between delivered dose and the sub-regions of the glands may be more meaningful 
[74], indicating the need for accurate estimation of the dose delivered to the PG sub-regions.  
 
HN patients lose 6-10% of their body weight on average over cancer treatment [141], leading to 
anatomical changes and deformation. Additionally, tumors shrink by an average of 70% of their 
initial volume by the end of radiation treatment [31]. Due to those complex anatomical changes 
throughout RT, the precise delivery of the planned dose is compromised. Especially, as the tumor 
can be situated near a PG, a sharp dose gradient over the PG can exist, where even a small shift or 
volumetric change could potentially lead to a dramatic difference in the dose. The delivered dose 
to the PG has been reported as high as 30% above the planned dose distribution [142]. This increase 
can be clinically significant, as a 1 Gy dose increase correlates with a 5% decrease in PG function 
[143]. Understanding the response of the PGs to the dose is then hampered by the differences 
between planned and delivered dose. 
 
Dose accumulation using deformable image registration (DIR) can be used to estimate delivered 
dose to the PG. Many studies investigated deformable image registration between the planning CT 
and followup CT or Cone-Beam CTs (CBCT) to accumulate the dose in the head and neck region 
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[125,144-146]. However, since only the boundaries of the gland are visible with these imaging 
modalities, the deformation estimated inside the gland is the result of a regularization model of the 
displacement vector field (DVF). Since a correlation exists between the mean dose and the volume 
change of the PG [147], the internal deformations of the gland may actually be more complex than 
an interpolation from the gland surface deformation, and may depend on the heterogeneity of the 
dose inside the gland and the variable sensitivity of the tissue in the gland. 
 
Previous studies modeled the dose response of organs by using dose-based boundary conditions 
into a biomechanical model-based deformable image registration algorithm, Morfeus [63]. Al-
Mayah et al demonstrated the feasibility of simulating a dose-induced shrinkage of the PGs for 5 
patients by assigning a negative thermal expansion coefficient to the tetrahedral elements of the 
PG in Morfeus and by applying to each element a temperature corresponding to the locally planned 
dose [136]. More recently, Polan et al investigated the use of additional dose-based boundary 
conditions on the liver [97] versus the use of boundary conditions on the liver surface only. The 
use of dose BCs, based on a model established from 33 prior radiation therapy patients, was 
evaluated for the DIR of pre- and post-RT CT scans for 7 patients. The target registration error 
(TRE) was significantly improved when using dose BCs suggesting the model better described the 
spatial volume change distribution inside the liver. 
 
The goal of this study was to establish the relationship between dose and PG shrinkage for a 
population of patients and to use that model to improve the DIR accuracy of longitudinal images 
of the PG during RT. MR images acquired at the time of treatment planning and mid-treatment 
were collected for a series of patients to visualize anatomical details inside the PG and allow 
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quantitative evaluation of the proposed method accuracy. The DVF differences in the PG, when 
considering dose-boundary conditions or not, were analyzed. 
 
 
 Materials and Methods  
 
6.3.1 Patient Data  
 
Nineteen patients treated at the MD Anderson Cancer Center with RT for oropharyngeal cancer in 
31-35 fractions were retrospectively evaluated. Detailed patient data are shown in Table 1.  For 
each patient, the following images were collected and imported in the treatment planning system 
RayStation: the treatment planning CT, planned dose distribution, a treatment planning MR and a 
MR acquired approximately at mid-treatment between fractions 15 and 25.  
 
   
Table 6-1. Treatment details for patients included in the study.  
BOT stands for base of tongue.  
Characteristic  Value 
RT modality (IMRT/Proton) 15/4 
Total dose (range, median) 63-72,70 
Total fractions (range, median) 31-35,33 
Treatment duration (range, median) 39-50,44 
Gender (M/F) 19/0 
Age (range, median) 32-78,67 
Tumor subsite (tonsil/BOT/neck) 11/6/2 
HPV/p16 status (+/-) 18/1 
Concurrent chemotherapy (yes/no) 13/6 
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1.1.1. Image data 
 
For each patient, all PGs were delineated on the MR images. In order to ensure consistency 
between the contours on the planning MR and mid-treatment MR, the PGs were first delineated 
on the planning MR and automatically propagated onto the mid-treatment MR using the intensity-
based DIR method available in RayStation. Manual edits were made on the propagated contour 
when necessary. The mandible, C1 vertebrae and C3 vertebrae were manually delineated on the 
planning CT. The contours of these bony structures were copied on the MR images following the 
global rigid registration and translated or rotated when necessary. The dose grid, rigidly registered 
MR images and all the contours for ten patients were exported from the treatment planning 
software for processing with an in-house implementation of Morfeus. 
 
For each PG, three corresponding anatomical landmarks were placed on the planning and mid-
treatment MR, with an effort to have them spatially well distributed. The landmarks were used to 
assess the registration accuracy by measuring, in each PG, the target registration errors (TRE) 
defined as the mean Euclidean distance between each pair of landmarks. 
  
1.1.2. Analysis of the dose volume relationship 
 
For the 38 PGs of the 19 patients in the optimization cohort, the volume of the gland was measured 
on both MR images and the planned mean dose was scaled to the mean dose delivered at the time 
of the mid-treatment MR. The relationship between volume change and mean delivered dose was 
analyzed. 
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6.3.2 Biomechanical Model-based Deformable Image Registration 
 
6.3.3 Neck flexion alignment 
 
Our previous work demonstrated that a global rigid registration of the HN anatomy could yield to 
a poor alignment of the PGs because of varying angles of neck flexion. The use of the 
biomechanical model-based DIR implemented in RayStation based on boundary conditions on 
only the mandible, C1 and C3 vertebras allowed to correct for that neck flexion and improve the 
alignment of the PGs. In this study, this approach was systematically applied to register the mid-
treatment MR onto the planning MR. The obtained 𝐷𝑉𝐹𝑓𝑙𝑒𝑥𝑖𝑜𝑛 were exported from RayStation and 
used to deform the contour of the PG corresponding to the mid-treatment MR. 
 
 
6.3.4 Standard Morfeus 
 
The in-house implementation of Morfeus [63] was used for this study. The workflow of the method 
is illustrated Figure 1. For each PG corresponding to the planning, Morfeus creates a tetrahedral 
mesh of the gland and surrounding anatomy. Based on previous studies, the Young’s Modulus, 
defined as the ratio of the stress to the strain(Eq. 6-1), was set to 7.8 kPa and the Poisson’s Ratio, 
defined as the ratio  between the transverse and axial strain (Eq. 6-2),  was set to 0.45. These 
properties were assigned to the PG elements.  
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 𝐸 =  
𝜎
𝜖
 (6-1) 
 
Young’s Modulus is defined by the ratio of the uniaxial stress, σ, to the strain, ϵ. 
 
 𝜈 =  −
𝜀𝑡𝑟𝑎𝑛𝑠
𝜀𝑎𝑥𝑖𝑎𝑙
  (6-2) 
 
Poisson’s Ratio is the transverse strain divided by the axial strain.  
 
A surface projection algorithm is applied between the PG surfaces of the planning and mid-
treatment after resolving the neck flexion. The displacements determined on the surface nodes 
are used as boundary conditions in the model to solve the displacement of all the internal mesh 
nodes in a finite-element analysis. The surface projection algorithm used for this study was based 
on the accelerated Demons algorithm [101]. The forces of the Demons method can be described 
using the optical flow equation. The following equation describes the displacement 𝑑 of a point 
from the reference PG, R, to the point corresponding from the target PG, T:   
 
 𝑑 =
(𝑡 − 𝑟)∇⃗⃗𝑟
|∇⃗⃗𝑟|
2
+ (𝑡 − 𝑟)2
  (6-3) 
 
 
where 𝑑 represents the displacement in each direction, t and r represent the intensities of the 
target and references PGs, and ∇⃗⃗𝑟 represents the reference PG gradient. The Demons algorithm 
 120 
solves the equation iteratively using optical flow and regularization of the DVF. The 
regularization component smooths, minimizes noise, and keeps the deformed image continuous. 
Since the deformation is driven only by the gradient of the reference PG, the method was 
improved [101] with the addition of an active force to the deformed (target) image. This active 
force, 𝑓𝑡⃗⃗⃗ ⃗, can be described in the following equation. 
 
 𝑓𝑡⃗⃗⃗ ⃗ =  − 
(𝑟 − 𝑡)∇⃗⃗𝑡
|∇⃗⃗𝑡|
2
+ (𝑟 − 𝑡)2
  (6-4) 
 
Finally, the total force of a point can be described with the equation 
 
 𝑓 = 𝑓𝑟⃗⃗⃗ ⃗ + 𝑓𝑡⃗⃗⃗ ⃗ = (𝑡 − 𝑟) ∗ (
∇⃗⃗𝑟
|∇⃗⃗𝑟|
2
+ (𝑟 − 𝑡)2
+
∇⃗⃗𝑡
|∇⃗⃗𝑡|
2
+ (𝑟 − 𝑡)2
) (6-5) 
 
where 𝑓𝑟⃗⃗⃗ ⃗ represents the force from the gradient of the reference PG and 𝑓𝑡⃗⃗⃗ ⃗ represents the force 
from the gradient of the target PG. These force calculations are appropriate with relatively small 
deformations. To account for larger deformations, the multiresolution method [102] was applied. 
This method applies an iterative demons diffusion approach, based on low-resolution images, 
and increases calculation speed by improving the convergence. An additional normalization 
factor (a) was also applied. With this incorporation of a, adjustments to the force strength at each 
iteration is possible. This factor is applied as shown in the following equation 
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 𝑑 = (𝑡 − 𝑟) ∗ (
∇⃗⃗𝑟
|∇⃗⃗𝑟|
2
+ 𝑎2(𝑟 − 𝑡)2
+
∇⃗⃗𝑡
|∇⃗⃗𝑡|
2
+ 𝑎2(𝑟 − 𝑡)2
) (6-6) 
 
where larger deformations require smaller a values.  
 
Finally, the calculated displacements are resampled on the grid of the planning MR image to 
provide a DVF mapping the PG voxels of the planning image to the mid-treatment image. 
 
Figure 6-1. Depiction of standard Morfeus process.  
The initial image is aligned to a corresponding image. A volumetric mesh is generated and material properties are 
assigned to the pre-treatment image. A surface mesh is generated from the mid-treatment image. A surface 
correlation is calculated and applied as boundary conditions to the pre-treatment model. FEA solves the deformation 
between the pre-treatment to mid-treatment PG image.  
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6.3.5 Modeling the dose-induced shrinkage 
 
Morfeus was expanded to simulate a shrinkage of the PG as a response to a dose distribution as 
illustrated Figure 2. For this, each tetrahedral element of the PG was assigned an additional 
material property a thermal expansion coefficient. Where the classic thermal expansion coefficient 
involves the change in temperature, the modified version 𝛼 applied in this study involves the dose 
to the PG:  
 𝛼 =
(𝑉𝑚 − 𝑉𝑖)
3𝑉𝑖𝐷
 (6-7) 
 
Where 𝑉𝑚 the volume of the gland at mid-treatment is, 𝑉𝑖 is the volume at planning, and 𝐷 is the 
mean dose to the PG.  
 
Optimization experiments showed that for the FEM solver to provide a stable solution considering 
the large volume variations to simulate, more compressibility of the tetrahedral elements had to be 
allowed by decreasing the Poisson’s ratio to 0.3 compared to a value 0.45 for standard Morfeus. 
 
After application of the dose-induced shrinkage as a first step (Figure 2), the post-response PG 
was used in a second step of a standard run of Morfeus (Figure 1.).  
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Figure 6-2. Depiction of dose-based boundary condition application to Morfeus.  
The modified thermal expansion coefficient is developed based on the population model. A FEM of the PG is 
created. Boundary conditions are applied to the FEM of the PG and the PG responds with the application of the 
boundary conditions from FEA. 
6.3.6 Displacement vector fields analysis 
 
After DIR using standard Morfeus (Morfeusstd) or Morfeus with additional dose boundary 
conditions (Morfeusdbc), the DVF was composed with the initial 𝐷𝑉𝐹𝑓𝑙𝑒𝑥𝑖𝑜𝑛 and the resulting DVF 
imported in RayStation for accuracy evaluation. 
 
The Jacobian matrix is computed based on the DVF. The determinant of the Jacobian matrix is 
then calculated to represent the volumetric change of each voxel based on the DVF. The Jacobian 
determinant is described with the following equation, where T is the deformation, x is the voxel 
coordinates at which the local expansion of compression the volume change is being calculated.      
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 𝐽𝑇(𝑥) = 𝑑𝑒𝑡
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 (6-8) 
 
In the case that the Jacobian determinant is greater than one, volumetric expansion has occurred. 
In the case that the Jacobian determinant is less than one, volumetric compression has occurred. 
In order to compare the distribution of the volume changes inside the gland between Morfeusstd 
and Morfeusdbc and to verify the correlation with the dose distribution when considering 
Morfeusdbc, the determinant of the Jacobian was computed for one PG example. 
 
 Results 
 
6.4.1 Population Model 
 
Figure 3 represents the measured volume changes versus the mean dose delivered at mid-
treatment for the 38 PGs included in the study. A linear regression with an intercept set at the 
origin yielded to an expansion coefficient 𝛼 = −0.0033 following Eq 1. 
 
However, experimentation showed that to achieve the final desired volume changes in 
Morfeusdbc, 𝛼 had to be scaled by a factor of 1.3. 𝛼′ = 𝛼 ∗ 1.3 = −0.0043 . 
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Figure 6-3. Population Model.  
Population model of the volume change (absolute) over the dose [Gy] for calculation of the modified thermal 
expansion coefficient. Each point represents a different PG.  
 
6.4.2 Target Registration Errors and Dice Similarity Coefficients 
 
Box plots of the TRE for the initial alignment based on the vertebrae and mandible, Morfeusstd, 
and Morfeusdbc are shown in Fig. 4. The initial alignment resulted in a mean TRE of 3.1 ± 1.6 mm. 
Morfeusstd resulted in an average TRE of 1.6 ± 0.9 mm. Morfeusdbc resulted in an average TRE of 
1.4 ± 0.8 mm, a statistically significant improvement (p = 0.01) over Morfeusstd., based on a 2-
Tailed paired Student’s T-Test.  
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Since Morfeus uses the contours of the PG, the Dice Similarity Coefficient (DSC) for the PG was 
always measured above 0.93 and no significant differences were found between Morfeusstd and 
Morfeusdbc. 
 
 
 
Figure 6-4. Resulting TRE for each DIR Method.  
The whiskers represent the maximum and minimum values. The middle line represents the median values. The 
bottom horizontal lines represent the first quartiles. The top horizontal lines represent the third quartiles.  
 
6.4.3 Jacobian determinant distribution and impact on dose mapping 
 
1.1.3. Volume change maps 
 
For comparison of the spatial volume change distributions, the Jacobian determinant maps were 
computed from the DVFs obtained after Morfeusstd, from the DVFs obtained after applying only 
dose BCs and from the DVFs obtained after Morfeusdbc.  
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Figure 5 represents for an example PG, the dose distribution on a coronal slice and the histogram 
of the doses in the whole gland as well the different Jacobian maps, their histogram and the 
correlation with dose distribution. 
 
A very low correlation between the dose distribution and the volume changes after Morfeusstd was 
found with a Spearman correlation coefficient r=-0.10. A very high correlation with r=-0.96 was 
measured after the first step of Morfeusdbc when only dose BC were applied, indicating that our 
method worked as intended.  
 
The correlation decreased after applying boundary conditions on the surface of the parotid gland 
in the second step of Morfeusdbc but remained relatively high (r=-0.62). 
 
For this patient, the volume change was 20%. The DSC was the same (0.96) for Morfeusstd and 
Morfeusdbc but the mean TRE improved when using Morfeusdbc from 1.6 mm to 1.0 mm, which 
supports our hypothesis of a correlation between dose and volume change distributions. 
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Figure 6-5. Jacobian Maps.  
Left column: Images of the dose and Jacobian maps for the same coronal slice of a PG. The white contour represents 
the PG. Middle column: Histograms of the corresponding images. Right column: scatter plots representing the 
correlation with the Spearman correlation coefficient r between the Jacobian map and the dose distribution inside the 
PG. 
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1.1.4. DVF differences 
 
The mean absolute DVF difference between Morfeusstd and Morfeusdbc inside the example PG 
(Figure 6) was 0.7 ± 0.3 mm and the 95th percentile was 1.4 mm. Small differences were found 
on the boundaries of the PG, as the surface projection method in each DIR method resulted in 
similar surface point-to-point correspondences.   
 
 
Figure 6-6. DVF Differences.  
Norm in millimeters of the vector differences between the DVFs obtained with standard Morfeus and Morfeus with 
dose BC on the same coronal slice as for Figure 6. 
 
1.1.5. Dosimetric impact 
 
To assess the impact of the DVF differences for dose mapping applications, the deformation fields 
obtained after Morfeusstd and Morfeusdbc were inverted and used to map the planned dose 
distribution from the planning MR to the mid-treatment MR. Figure 7 represents the absolute 
difference between the mapped dose distributions on the same coronal slice as previously and the 
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dose-volume histograms. While the DVF differences could be considered small, these differences 
translated for this example into impactful dosimetric differences. For example, D50, the minimum 
dose received by 50% of the volume was 17 Gy and 20 Gy for Morfeusstd and Morfeusdbc 
respectively. 
  
 
 
Figure 6-7. Dose Distribution Differences and DVH.  
Left: Image of the absolute differences in Gy between the dose distributions mapped from the planning image to the 
mid-treatment image considering standard Morfeus or Morfeus with dose BCs. The white contour represents the 
contour of PG from the mid-treatment MR. Right: Comparison between the dose-volume histograms. 
 
 Discussion 
 
A biomechanical model-based DIR method has been expanded to describe the dose-induced 
shrinkage of the PGs due to RT. Following initial alignment of the PGs, the first step of this DIR 
method involved applying the dose-based boundary conditions to the PG of the planning MR. 
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The second step consisted of applying boundary conditions on the PG surface to refine the 
deformation. The calculation of the Jacobian map of the final deformation field demonstrated 
that our numerical implementation provides the desired volumetric response behavior of the PG. 
The accuracy of the method was assessed by measuring the TRE. However, in MR images 
identifying landmarks can be challenging, which limits the comprehensiveness of this evaluation.  
The addition of MR sialography, which improves the conspicuity of the vessels in the PG, would 
aid in this effort.  Work is ongoing to develop these sequences and acquire them in future clinical 
trials.   
 
The hypothesis of this study was that the volume change inside the PGs depends on the dose 
distribution, with the tissues receiving higher dose being more likely to shrink than tissues in low 
dose regions. To test this assumption, the accuracy of the proposed DIR method using dose 
boundary conditions was compared to the accuracy of the standard DIR method based only on the 
surface boundary conditions. Both DIR methods resulted in similar DSC, but the statistically 
significant improvement in TRE using the expanded DIR method confirms our hypothesis, even 
in this limited cohort of patients. Consequently, traditional DIR methods based only on the PG 
boundaries may lead to inaccurate estimations of deformation inside the gland, and therefore 
inaccurate estimates of the delivered dose. 
 
This study used MR images to enable the identification of internal landmarks for TRE evaluation.  
However, MR images are not always available for patients and therefore DIR must be performed 
on CT images, where internal landmarks are not visible. The method proposed here will maintain 
a consistent level of accuracy regardless of imaging modality, as long as the PG boundaries can be 
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identified as it only relies on the boundaries of the PG and the planned dose distribution. Having 
a robust algorithm is critical to enable widespread deployment of dose accumulation in the PG. 
 
Although the average TRE improvement was modest, 1.6 mm to 1.4 mm, the new deformation 
model can yield to clinically meaningful dose differences, as illustrated in the highlighted patient. 
Future work will also investigate if the dose estimated with the proposed deformation model will 
lead to better predictors of the toxicity.  
 
 Conclusion  
            
A model was developed to describe the volumetric response of the parotid glands to radiation 
dose, using dose-based boundary conditions, applying shrinkage based on radiation dose to each 
tetrahedral element in the model. This model had improved results over the standard 
biomechanical model-based deformable image registration algorithm, as well as a higher 
correlation between the volumetric change inside the gland and the radiation dose. The use of 
this model, applied to images with clear ductal anatomy, could allow for dose accumulation to 
the substructures of the parotid glands. Dose accumulation to substructures of the parotid gland 
can be correlated with predicted toxicity for the glands. Ultimately, more accurate toxicity 
models could be developed based on this work.  
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Chapter 7. Conclusions and Future Work 
  
 Conclusions  
 
In chapter 2, the need for prospective clinical trials to evaluate the clinical impact of developing 
NTCP models based on accumulated dose, rather than planned dose, was demonstrated. The 
study used simulated data for 600 patients to develop toxicity models and indicated that 
historical NTCP models, based on planned dose, may overestimate the toxicity risk for lower 
doses, but underestimate the risk of toxicity for higher doses with errors up to 21%. The 
differences between NTCP models based on accumulated dose compared to NTCP models based 
on planned dose is greater for duodenum than for stomach. However, with the availability of 
deformable registration-based dose accumulation using volumetric daily imaging, improved 
NTCP models are possible and should be included in the development of future clinical trials. 
 
With the use of this model developed in chapter 3, HN cases that would benefit from replanning 
could be identified. For submandibular glands, a dose deviation threshold of 3.5Gy at fraction 15 
can predict the need to replan a patient. Therefore, a model was developed to aid physicians in 
the decision to replan HN patients based on the submandibular glands by fraction 15 of radiation 
treatment. At least one organ exceeded the dose deviation threshold for all CBCTs in which a 
DIR failure was identified, indicating the possibility of an automated process to perform DIR 
evaluation only for cases that would result in a dose deviation. Additionally, the accuracy of the 
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DIR algorithm in the commercial treatment management software was evaluated using contour 
propagation.  
 
This retrospective study in chapter 4 demonstrated that PG deformation due to neck flexion can 
be modeled using the biomechanical model-based method with indistinguishable results from the 
intensity-based method (p=0.13 for volume change up to 20%). The minimum DSC based on the 
biomechanical-based method is 0.53, while the minimum DSC based on the intensity-based 
method is 0.17. This combined with the many outliers from the intensity-based method shows 
that while the intensity-based method can slightly outperform the biomechanical model-based 
method on average, there can be substantial failures using the intensity-based method, which is 
not observed with the biomechanical model-based method. The biomechanical model can be an 
initial step in a comprehensive model to describe the anatomical, patient positioning, and 
volumetric changes to the salivary glands during HN radiation therapy, and eventually aid in the 
development of toxicity models for this region.  
 
In chapter 5, a biomechanical model-based DIR method was developed to describe the volumetric 
response of the PG to RT. A modified thermal expansion coefficient was applied to an existing in-
house biomechanical model-based DIR algorithm. The adaptation to the existing DIR method 
improved the average TRE significantly (p = 0.01) from 1.6 mm ± 0.9 mm to 1.4 mm ± 0.8 mm, 
which should translate into better estimations of the delivered dose through the course of radiation 
therapy and potentially in the development of more accurate toxicity prediction models.  
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 Summary and Future Work 
This dissertation consisted of a series of experiments based on finite element modeling that lead 
to better understanding of the uncertainty between planned and delivered radiation dose and the 
development of improved statistical models of toxicity. This work aimed to improve the 
understanding of toxicity during liver cancer radiotherapy by quantifying deviations between 
accumulated and planned dose in luminal NTCP models, develop predictive models for 
treatment replanning decisions in head and neck treatments, resolve the anatomical changes due 
to neck flexion using biomechanical modeling, and develop biomechanical models of dose 
response of the parotid glands in order to improve toxicity prediction models. The studies 
described were novel and will hopefully lead to continued development and advancement. Three 
paths of interest are detailed below. Briefly, future directions include applying the models 
previously described throughout this manuscript to additional anatomical sites. Another path 
involves the use of imaging modalities that were not explored throughout this dissertation. 
Finally, a long-term goal for future work related to this thesis includes clinical trials to expand 
the patient cohorts studied in the previous chapters.  
 
The models developed for this dissertation were based on the abdominal region and the HN 
region. Further studies should explore other organ regions to improve toxicity risk of patients 
affected by those cancers, as well as to enhance the robustness of biomechanical models. One 
such organ site is the brain. Common brain cancers include glioblastoma multiforme (GBM), 
which is a type of glioma. Gliomas are cancers of the glial cells in the brain. GBM is an 
infiltrative tumor, and tumor cells can be found far beyond the margins visible on medical 
images. The brain is comprised of a large number of critical structures which are typically not 
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visualized on standard imaging. Determining the correlation between the dose to these critical 
structures and toxicity is essential for the QoL of the patient. However, it would not be feasible 
for a radiation oncologist to contour all of these structures for each patient during radiation 
therapy. There exists the need for an atlas of normal tissue contours that can be mapped onto 
each patient that undergoes radiation therapy for brain cancer, to spare these critical brain 
structures and preserve the patient’s QoL. Biomechanical model-based DIR could aide in the 
development of such an atlas. Preliminary work of applying biomechanical model-based DIR to 
glioma patient images included post-surgery/pre-radiation therapy and post-radiation therapy 
images. Boundary conditions were placed on the GTV and brainstem in order to align normal 
structures. For one patient with substantial normal tissue shifts due to a reduction in swelling 
from the pre-radiation therapy image to the post-radiation therapy image, boundary conditions on 
the GTV alone yielded a DSC improvement from 0.56 to 0.74, 0.36 to 0.48, and 0.68 to 0.71 for 
rigid registration to DIR in the ventricles, left hippocampus, and right hippocampus, respectively. 
Applying the brain stem and GTV as boundary conditions for the other patients in the study 
slightly improved the alignment of the normal tissues. Boundary conditions on the surgical 
resection cavity are also being explored for this study.     
 
The work presented in this dissertation was based on CT and MR images. However, several 
other imaging modalities are used in the diagnosis and treatment of cancer. Namely, MR-
sialography (Figure 1), which is an imaging technique that relies on the bright signal produced 
from fluids on heavily T2-weighted images (TR = 3500 and TE = 500 ms). This imaging 
modality can be useful in the imaging of HN cancer, as the salivary flow can be visualized. 
Patients receiving imaging of this type are given vitamin C to stimulate salivary output and 
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improve the visibility of the salivary ducts. As the parotid and submandibular glands produce 
saliva, they can be successfully imaged using this technique, as shown in Figure 1. Future work 
involves using this imaging modality to obtain a detailed representation of the parotid gland 
anatomy. The segmentation of the salivary duct tree will allow a more thorough evaluation of the 
accuracy of the parotid gland shrinkage model proposed in this Ph.D. work by measuring how 
well the biomechanical model matches the whole duct tree and not only a limited number of 
manually picked landmarks. Using the duct segmentation to place additional internal boundary 
conditions in the proposed biomechanical model will also be investigated to evaluate the 
accuracy of the image alignment. The dose response assessment could be improved considering 
this advanced detailed image modality.  
 
Figure 7-1. Examples of sialography images.  
On the left is an axial slice depicting a bright parotid gland duct. In the middle is a sagittal view. On the right is a 
coronal view. The red arrow points to the location of the parotid gland duct.  
 
Ultimately, applying the models developed throughout this Ph.D. to larger patient cohorts will be 
instrumental in validating these models for use in the clinic. This thesis work included the first 
model of normal tissue complication probability based on accumulated dose, which is now 
possible on a large scale due to recent technological advancements. This work involved a cohort 
of thirty patients, which were resampled to project the potential effect of using accumulated dose 
 138 
for NTCP curves in place of the standard planned dose. The study demonstrated the potential 
clinical importance of including accumulated dose in the development of NTCP models in future 
clinical trials, in which the delivered (accumulated) doses and toxicity outcomes would be 
prospectively recorded to improve the understanding of the dose-response relationship. Such a 
trial could characterize the differences between planned and accumulated dose values and the 
true impact of these differences on NTCP models. Clinical trials for cancer research are 
conducted by a non-profit research organization, for example NRG Oncology. A phase III trial 
can include hundreds of patients assigned to either the standard or new treatment, with the goal 
of determining if the new treatment is an improvement over the standard. If daily imaging was 
collected for each patient undergoing a phase III trial for a new fractionated radiation treatment 
method, dose accumulation could be performed in order to correlate the accumulated dose with 
toxicity. With accumulated dose tabulated for hundreds or thousands of patients, more accurate 
toxicity models could be developed. One ongoing NRG trial for the treatment of liver cancer is a 
phase III randomized trial to study the efficacy of photons versus protons in overall survival for 
HCC patients. Another current phase III randomized trial is comparing Sorafenib 
(chemotherapy) with SBRT followed by Sorafenib in HCC patients to investigate if overall 
survival is improved when SBRT is used in addition to Sorafenib. In addition to NTCP 
modeling, this thesis also includes the first ever predictive model to aid in the decision to replan 
head and neck patients, where the current decision to adapt is based on the physician’s ‘best 
guess’ and has no standardized metrics or guidelines to assist in this complex task.  These HN 
predictive models, described in the second chapter of this thesis, require prospective validation in 
a larger, multi-institutional patient cohort. The model was developed based on 100 HN cancer 
patients treated at the University of Michigan and externally validated on 52 patients treated at 
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the MD Anderson Cancer Center. The development of adaptive clinical trials utilizing these 
predictive models are currently under development.  
 
Finally, this work included the first dose response study of the parotid glands that included 
internal validation inside the organs. First, 100 patients were aligned based on bony anatomy, 
and next the volumetric response was added to the model. Accurate modeling of the parotid 
gland during radiation therapy, which is complex due to the dose functions, will allow a better 
estimate of the delivered dose distribution inside the parotid gland. Ultimately, these models will 
yield better understanding of the toxicity and dose relationship and will allow the development of 
better predictive models to be used in advanced adaptive radiation therapy strategies. No other 
approach currently accounts for the dose distribution inside the gland.  These studies also require 
validation on a larger cohort of patients to be used clinically.  A linear relationship was found 
between the volumetric change and mean dose to 40 parotid glands. However, more data points 
could show a more complex relationship. One patient in this cohort had a very high dose of 40Gy 
to the left parotid gland. The addition of more patients could provide more data points with very 
high dose. With a larger population model, the dose-response model would be more robust.  
 
To summarize, this dissertation proposed original approaches to describe the uncertainties 
between planned and delivered dose during radiation therapy and demonstrated their utility for 
advanced adaptive radiotherapy techniques. There will be more detailed imaging involved in the 
management of cancer treatment, as in the case with the MR-linear accelerator, which provides 
real-time high-resolution imaging during radiation therapy,  providing the opportunity to further 
demonstrate the refinement and use of these models. 
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